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ABSTRACT 
Infection by Human Immunodeficiency Virus (HIV) is a multifactor disease 
process in which the patient must confront an array of physiological, socio-
cultural, economic, and psychological stressors that have the collective 
potential for triggering major stress responses and psychological dysfunction. 
People's reactions to and the outcomes of traumatic events are mediated by 
their subjective style of coping. Coping is defined as a person's "constantly 
changing cognitive and behavioral efforts to manage specific external and 
internal demands that are appraised as taxing or exceeding the resources of a 
person". Coping, an important psychological construct has been shown to 
affect outcomes such as disease progression and quality of life in HIV infected 
patients. But the subjective styles of coping that patients use to cope with HIV 
have rarely been assessed as predictors of medication adherence. This study 
aims at determining the role of coping styles as determined by the "Ways of 
coping questionnaire" modified by Dunkel-Schetter et al. to suit their study of 
cancer patients as predictors of medication adherence in patients infected 
with HIV. The five dimensions of coping identified by Dunkel-Schetter et al. 
were the first to be identified with a large sample of cancer patients and may 
be representative of the universal dimensions of coping. This study is the first 
to utilize the dimensions of coping as described by Dunkel-Schetter et al. to 
predict adherence in HIV patients. The few studies on coping styles and 
adherence as an outcome use varied coping scales to assess coping like the 
Billings and Moos coping inventory and original Ways of coping 
( questionnaire. Their results have shown that poor copmg strategies like 
avoidance coping were associated with non-adherence. 
Methods: The sample for the study consisted of 145 patients who were 
currently prescribed medication for HIV. The medication adherence shown by 
patients with anti-retroviral drugs and protease-inhibitor drugs was assessed 
separately. A total of 137 patients were on anti-retroviral drugs, while 77 
patients were on protease-inhibitor drugs. Medication adherence was 
determined by using the "percentage of doses missed in the past three months 
and "Medication Adherence Scale. Coping strategies used by the patients 
were assessed by the "Ways of coping questionnaire" developed by Lazarus 
and colleagues and later modified by Dunkel-Schetter et al. to suit their study 
of cancer patients. The scale comprised of five coping sub-scales: seeking 
social support, distancing, focusing on positive, behavioral escape avoidance 
and cognitive escape avoidance and assessed the frequency of use of each 
coping style. Several demographic variables as well as clinical variables, 
which are known to affect medication adherence, were examined. Logistic 
Regression analyses were used to determine whether the coping strategies 
were predictive of medication adherence controlling for the confounding 
factors . 
Results: In agreement with previous research that shows that poor coping was 
associated with non-adherence, for the patients prescribed antiretroviral 
medications, behavioral escape avoidance was found to be significantly and 
inversely associated with adherence. Seeking social support, distancing, 
focusing on positive and cognitive escape avoidance were not found to be 
significantly associated with medication adherence. 
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( INTRODUCTION 
Acquired Immunodeficiency Syndrome (AIDS) is a devastating disease facing 
humankind. Since the epidemic started in 1981, more than 60 million people 
worldwide have been infected with the Human Immunodeficiency virus (HIV), 
which causes AIDS. Worldwide, AIDS is the fourth leading cause of death. In the 
United States, approximately 1 million people are either infected with HIV or 
have AIDS. In the United States, the incidence of HIV is approximately 40 
thousand cases every year. Thus, HIV infection and AIDS are significant public 
health problems and challenges. (1) 
Until quite recently, the disease was considered to carry an almost certain 
debilitating, downward course leading to early death from opportunistic 
infections. A variety of medications were used to treat HIV related diseases, and 
some such as Zidovudine could temporarily suppress levels of HIV responsible 
for immune compromise. However the treatment only produced transient benefits 
because the circulating HIV remained in enormous quantity and the virus has a 
rapid error prone replication cycle that allows it to quickly evolve resistance to 
any single drug. The nature of medical care changed dramatically in 1996 with the 
development and wide use of treatment regimen that added a new class of anti-
retroviral medication called protease inhibitors in combination with other anti-
retroviral medications (2). Highly Active Anti-retroviral Therapy (HAART), 
usually a protease inhibitor combined with at least two other drugs, controls the 
viral replication by targeting specific viral enzymes. There are currently two 
distinct groups of anti HIV drugs that are targeted at different viral enzymes. 
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These are reverse -transcriptase inhibitors and protease inhibitors (3). HAART 
has enormous potential to delay disease progression and death (4). HAART is 
designed to suppress HIV viral replication, which results in increases in CD4 cell 
count, improved immune function, delayed clinical progression, and prolonged 
survival (5,6). Successful treatment of HIV with HAART requires that patient 
maintain nearly perfect adherence to the prescribed regimen. Adherence, often 
used interchangeably with compliance, is "the act, or quality of being consistent 
with administration of prescribed medication". Non- adherence may mean not 
taking medication at all, taking reduced amounts, not taking doses at prescribed 
frequencies or intervals or not matching medication to the food requirements (7). 
A] Important of Adherence 
Adherence to HAAR T is the single most important factor for achieving 
maximum and durable HIV plasma viral load suppression. Several studies have 
demonstrated that lapses in anti-retroviral adherence lower the likelihood of 
suppressing viral loads below detectable limit (8). Non-adherence leads to 
increased mortality and morbidity. A study by Hoggs et al. (9) reported a 16% rise 
in mortality for every 10% drop in adherence. 
Strict adherence to HAART is imperative because the therapy is 
"unforgiving" in two respects. First, m non-adherent patients, resistant viral 
strains develop because of high rates of viral mutation and the short half-life of 
the drugs (10). Condra et al. (11,12,13) reported that resistance might develop 
after missing as little as one dose in five. The genetic mutations that result in drug 
resistance often confer resistance to an entire class of protease inhibitors or non-
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nucleosides. Thus, in failing one regimen, a non-adherent patient may severely 
limit future antiviral options (10). Secondly, the level of adherence that must be 
achieved and maintained for maximal effectiveness exceeds that needed for 
effective therapy in many other chronic conditions. With HAART, patients must 
maintain near- perfect adherence to maintain an undetectable viral load (10). A 
study by Paterson et al. reported only 50% patients with 80%-90% adherence 
achieved undetectable viral loads. Patients required better than 95% adherence to 
achieve highest rate of undetectable viral load ( 14). The development of resistant 
strains is also a significant public health concern because of the possibility of 
transferring the resistant strain to others. Evidence was reported documenting the 
sexual transmission of virus resistant to all known classes of anti-retroviral drugs 
including protease inhibitors (15). In a prospective study of 93 patients, self 
reported adherence was independently associated with undetectable seminal HIV 
RNA level after six months of therapy (16). 
One hundred percent adherence to HAART is not easy to achieve. Studies of 
HIV/AIDS patients have reported low adherence rates. In a cross sectional study 
by Mostashari et al (17), involving 102 HIV infected females, 62% females 
reported taking all medications for >= 6 days a week, and were classified as 
adherent. In an observational cohort study called the ATHENA study (18), 
adherence to HAART was obtained by self-report and validated by blood assays. 
Of the 224 patients, 53. l % reported taking all the medications on time, and also 
followed dietary requirements for the last week. The rest reported missing doses 
or not taking them on time and were classified as non-adherent. In a study on 46 
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patients with HN, Singh et al. (19) reviewing monthly prescription fill records 
assessed adherence to antiretroviral therapy. All patients filling >=80% of their 
medications were defined as being adherent. With this criteria, 63% patients were 
adherent. In a study that of 180 patients randomized into either MEMS, diaries 
and no surveillance groups, the adherence in the past four weeks was 80.6%, 92% 
and 93% respectively (20). In a retrospective study of pharmacy claims data 
regarding prescription fills to assess adherence to HIV medications, only 26% 
patients had more than 80% adherence. Adherence was defined as proportion of 
days on which drugs were taken during the first 365 days on therapy. The mean 
adherence was 53% (21). Thus, the adherence has been found to be less than 
adequate. 
B] Assessment of adherence 
A major problem in studying adherence is the lack of a standard measure (8). 
There is no "gold standard" for measuring adherence. The four methods used 
most commonly to measure adherence are self reported (questionnaire/ interview/ 
diary), pill counts, drug assay, and electronic monitoring. 
Self Reported Questionnaires: It is the most common, inexpensive and simple 
method of determining adherence (22). Advantages of this method include low 
costs, easily obtainable results and flexibility to tailor the method to the language 
and reading competency of the subjects (23). Patient self reports are often the only 
available method. However, the validity of this measure is questionable. In 
general, self- reports tend to overestimate adherence compared with other 
methods of determining adherence, like pill counts or electronic monitoring. 
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Recall bias is another concern (23). Among HIV-infected patients however, there 
tends to be a strong correlation between self-reports and virologic outcomes. 
Though this method may not be as accurate as desired, there may be reason to 
believe that it is useful because patients reporting non-adherence are usually at 
least as non-adherent as indicated by interview (24). 
Pill Counts: Having a physician, nurse or other health care practitioner count pills 
remaining in a bottle is another way to measure adherence (8). This method 
involves a comparison of the medicine left in the bottle and the quantity that 
should have been left if the medication had been taken. The advantage of this 
method is that they are potentially affected less than the other methods by 
subjective patient response (8). Adherence assessed by this method correlate 
better with that measured from electronic bottle caps than does self-reported 
adherence (25). However, this method had several limitations. Patients may forget 
to bring their bottles to the clinic when instructed. It is very time-consuming. 
Patients may empty the bottle or may take all the remaining pills before the visit 
to the clinic (26). 
Drug assay: Plasma and urinary blood levels provide useful objective assessment 
of adherence (27). The accuracy of this method depends in part on the half-life of 
the drug (26), which is the time required for the potency of the drug to fall to half 
or to be eliminated from the body. This means that it depends on how soon the 
drug reaches the systemic circulation so as to be detected in a drug assay. These 
studies are very inconvenient and expensive. Some patients may object to having 
their blood drawn, regarding this as unnecessary and intrusive. Also, patient-to-
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patient variability is a drawback (28). In addition, results may be confounded by 
pharmacokinetic factors, such as poor drug absorption or drug -drug interactions, 
which may mimic poor adherence (8). 
Electronic monitoring: Bottles fitted with caps harboring electronic chips that 
register each time a pill bottle is opened or closed constitute the most 
sophisticated method currently available for measuring adherence. Two systems 
are available: Medication Event Monitoring System (MEMS) and the eDEM 
monitor (8). Data from the MEMS allows calculation of 1) the adherence rate, 2) 
prescribed frequency, and 3) prescribed interval. This measure also does not 
directly measure whether the patient took the medication; hence the accuracy of 
this method is suspect (26). 
C] Determinants of Adherence 
Given the importance of adherence with medication regimen in the success of 
HAART, most research in medication adherence in HIV infection has focused on 
predictors of adherence and factors affecting adherence. These factors can be 
classified as patient characteristics, clinical characteristics, treatment regimen 
characteristics, clinician and clinician-patient relationship and psychological and 
emotional characteristics. 
Patient Characteristics: The literature on adherence strongly and consistently 
demonstrates that adherence cannot be predicted solely on the basis of gender, 
age, race or educational status (29). Factors that affect the initiation and adherence 
to anti-retroviral therapies are knowledge and beliefs about the disease and 
medication, social support, co-morbid conditions, substance abuse, cognitive 
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impairment, depression and other mental illnesses (5). Thus adherence is may not 
related to income, social class, occupation or educational background and nor can 
it be accurately predicted by physicians (30). In a pilot study to test the effect of 
behavioral medical management of adherence, self reported adherence in the past 
four days improved from a mean of 80% to 98% in the group receiving behavioral 
based intervention of education about the therapy, positive reinforcements and 
encouragement, counseling and life style assessments (31). Thus knowledge about 
therapy and positive reinforcement enhance adherence 
Clinical Characteristics: After a critical literature review, Haynes (29) 
commented that there are few associations between disease features and 
adherence. The only exception being that when patients get better from any illness 
they are less likely to adhere to treatment regimen (32,33,34). 
Medications are more likely to be taken for short term, symptomatic illnesses, 
where there is a more easily appreciated direct connection between medication 
and therapeutic effect. (35). 
Treatment regimen characteristics: It has been well documented that the 
likelihood of adherence declines with an increase in the number of medications, 
frequency of dosing, severity of side effects, and complexity and anticipated 
duration of side effects. The more the regimen requires alterations or disruptions 
in daily routines and lifestyle, the less likely will be excellent adherence (36). 
Unfortunately, these negative characteristics are associated with the current, 
complex anti-retroviral medication regimen. Combination anti-retroviral 
medication regimen involve large number of pills with varying dosing schedules, 
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( food requirements, lifestyle rearrangements and lifelong administration (5). 
Furthermore, there are numerous side effects associated with the therapy. These 
include nausea, vomiting, anemia, granulocytopenia, pancreatitis, peripheral 
neuropathy, oral stomatitis, malaise, skin rash, and fever, to name a few (3). 
Psychological and emotional characteristics: 
a) Mood status is an important predictor of adherence. A level of anxiety 
either too high or too low may be related to non-adherence (37). Many cognitive, 
psychosocial factors as well as well being and quality of life also have impact on 
adherence. 
b) Coping: The concept that susceptibility to, and infectious diseases may be 
influenced by psychological factors has a very long history. The historical basis 
for studying the relationship between psychological stress and the immune 
response has been noted from centuries of clinical observations of individuals 
who became sick following stressful situations. Infection by HN is a multifactor 
disease process in which the patient must confront an array of physiological, 
socio-cultural, economic, and psychological stressors that have the collective 
potential for triggering major stress responses and psychological dysfunction (38). 
Individuals suffering from a chronic medical condition face a variety of stressful 
life circumstances involving a range of adaptation demands (39). Infection with 
HIV raises a wide spectrum of concerns and fears among infected individuals. 
Even before symptoms occur, those infected with HIV have concerns about the 
future economic security, sexuality and disease transmission, rejection from 
family, friends, lovers; and eventually ill health and death ( 40). Diagnosis of HIV 
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is a traumatic event as it not only presents the possibility of death, but also raises 
fears regarding changes in appearance, body functioning, role and self esteem 
(41). The uncertainty of the outcome of the infection can lead to anxiety. 
Reaction of others to the patients' diagnosis constitutes a significant concern 
(Ross and Rosser, 1988). In addition, individuals may not be able to conceal their 
illness from significant others if their symptoms are severe. They may need to 
take time off from work or stop working altogether. Such changes may lead to 
cessation of employer sponsored health insurance benefits, social supports, 
contact with acquaintances and income. The stresses of giving up work are 
considerable, often leading to depression and lack of self-esteem ( 42). 
Chronically ill patients must cope with the loss of independence, the threat of 
disease progression, and in most cases, the challenge of modifying their behavior 
to meet the demands of prescribed medication regimen. Patient adherence to a 
prescribed regimen can involve a range of adaptive tasks including dietary 
change, use of medication and change in physical activity (43). 
People's reactions to traumatic events are mediated by their subjective style of 
coping (44). For this study, the conceptualization of coping is based on the work 
of Lazarus and his colleagues. In Lazarus and Folkman's transactional stress and 
coping model, stressors themselves do not predict unfavorable outcomes, but 
rather how one appraises and copes with them determine to some extent their 
impact on one's health and well-being. Within this model, coping is defined as a 
person's "constantly changing cognitive and behavioral efforts to manage specific 
external and internal demands that are appraised as taxing or exceeding the 
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resources of a person" (44). Thus, coping refers to an individual's cognitive and 
behavioral efforts to manage specific situations that are appraised as stressful. The 
reaction and outcome for a particular outcome will depend on the subjective 
appraisal of the stressor and the coping style used. 
Coping styles have been consistently related to mental health adjustments and 
other health outcomes. Many studies have investigated the relationship between 
styles of coping and subsequent health in HN. For example, Ironson et al. found 
that reaction to the news that one was seropositive for HIV with denial was 
associated prospectively at one-year follow-up with greater CD4 decline and 
lower T cell proliferative response and with a greater likelihood of symptoms or 
death after two years (45). Conversely, Blornkvist et al. found that 'active 
optimistic coping' was negatively related to mortality over 1-7 years in a 
hemophiliac cohort ( 46). A study by Goodkin et al. on eleven asymptomatic 
HIV+ patients proved that passive coping styles were associated with lower total 
lymphocyte count and thus may also be predictor of development of AIDS (47). 
Thus considerably body of evidence suggests that psychological factors and 
coping play an important role in progression of HIV infection, its morbidity and 
morbidity. Many researchers have explored the effect of coping on many varied 
outcomes, but not much work has been carried out to explore the association of 
coping styles with medication adherence. Christensen et al ( 48). explored the 
adherence behavior and coping style preferences among renal dialysis patients. 
Adherence was predicted to be maximized in cases in which the patients' 
preferred style of coping matched the type of treatment they received. Planful 
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problem solving, a type of coping strategy was associated with more favorable 
adherence ( 48). In a longitudinal observational study involving 46 HIV positive 
patients, Singh et al. found that patients who were compliant with their 
medications had significantly better adaptive coping (19). In another study 
involving 123 HIV positive patients, Singh et al. reported that refill compliance 
with antiretroviral medications was significantly associated with problem focused 
coping ( 49). The limited studies on coping styles and adherence have been very 
varied in the use of coping scales to determine coping styles. No study has 
assessed the coping scales 'seeking social support', 'focusing on positive', 
'distancing', 'behavioral escape avoidance', 'cognitive escape avoidance' as 
predictors of adherence. Also, in the study by Singh et al. (19), the sample 
comprised of only males. Coping needs to studies on a representative sample to 
make the results generalizable. 
Measurement of coping strategies includes standardized instruments, interviewing 
protocols or observational techniques that assess the use of coping strategies to a 
specific stressor (50). Many instruments have been developed to determine the 
coping strategy used by people. The "ways of coping questionnaire" is one of the 
standardized instruments that have been used extensively as a research instrument 
in studies of the coping process. It has been derived from a cognitive-
phenomenological theory of stress and copmg developed by Lazarus and 
colleagues (51). This measure consists of a series of predicates, each of which 
portrays a coping thought or action that people sometimes engage in when under 
stress. This instrument and its modifications have been used in many studies in a 
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variety of settings. For example, Vitalinio et al. used the instrument to determine 
coping as an index of illness behavior in panic disorders (52). This scale was 
revised by Lazarus, Folkman, and Dunkel-Schetter to develop a questionnaire 
with 51 items. This scale was again modified by Dunkel-Schetter, Feinstein, 
Taylor and Flake (53) to suit their study on cancer patients. These were the first 
coping patterns to be identified with a large and heterogeneous sample of cancer 
patients and they are similar to those identified with a large sample of community 
residents experiencing a variety of life stressors. It appears that they may be 
representative of universal dimensions of coping. The five factors developed as a 
result of factor loadings were: seeking social support, distancing, focusing on 
positive, cognitive escape avoidance, and behavioral escape avoidance. In this 
study, these factors will be assessed as a predictor of medication adherence. There 
is great variability in the assessment of coping. This study shall add to the 
understanding of coping styles used by the HN patients and also to the adherence 
behavior and predictors of the same. 
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METHODOLOGY 
A. Study Setting and Sample 
The sample consisted of 145 patients who were currently prescribed medication 
for HIV. The eligibility criteria for this study included age between 18 and 74 
years, current use of approved antiretroviral medications or protease inhibitors, or 
use of approved medication for HIV- related complications and prophylaxis of 
opportunistic infections (for example, trimethoprim, sulfamethoxazole used in the 
prophylaxis of Pneumocystic carnii pneumonia), ability to read English, and a 
positive HIV status. 
The purpose of the original study was to develop measures of stages of change for 
medication adherence. The study was funded by the National Institute of Health 
(NIH) and was conducted by Dr. Cynthia Willey, University of Rhode Island, 
during 1995 to 1998. 
Patients were recruited from three sites affiliated with the study investigators. 
These sites are a part of seven clinical sites in Rhode Island, which have 
collaborated since 1987 as part of the Brown University Aids Program and 
provide primary care services to over 75% of the HIV infected patients from 
Rhode Island and the surrounding Massachusetts area. The study sites are listed 
below: 
1. The Miriam Hospital Immunology Center, which has the largest number of 
ambulatory visits of HIV seropositive individuals and serves the majority of 
HIV positive women in Rhode Island. 
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2. Stanley Street Treatment and Resources, which provides primary care for 
the indigent and intravenous drug users in the greater Fall River, 
Massachusetts area. 
3. Veteran's Affairs Medical Center in Providence, RI, which currently 
provides care to approximately 60 HN positive seropositive men. 
B. Data Collection 
A standardized questionnaire was administered to patients meeting the eligibility 
criteria who visited one of the three sites. The patients were told that the 
questionnaire was about how they think and feel about their HN related 
medications, and about different strategies that people use to take their 
medications. Research assistants explained the questionnaire to the patients in a 
private location on each site, and were available to answer questions while the 
respondents were filling out the questionnaire. 
Some patients did not complete the questionnaire at the clinic and were allowed to 
fill out the questionnaire at home and mail it to the clinic. They were told that 
they would each receive a $20 gift certificate after they had turned the 
questionnaire in. The data was collected during the year 1996-97. 
The survey questionnaire administered to the patients included questions to gather 
data on demographics, living arrangements, education, employment, income, 
insurance coverage, social support, side effects, and psychological measurement 
scales. The information about the medication and several adherence related 
questions were asked for each antiretroviral and protease inhibitor medication the 
patient was on. The respondents responded to a set of questions for every drug 
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they were prescribed. Of the 145 respondents, a subset of 77 respondents 
responded to questions on protease inhibitor medications m addition to 
antiretroviral medications. Thus, each respondent answered questions about each 
drug they were on separately. The medications the respondents provided 
information on included antiretroviral medications like AZT (retrovir, 
zidovudine), DDI (videx, didanosine), DDC (hivid, zalcitabine), D4T (zerit, 
stavudine), 3TC (epivir, lamivudine) and protease inhibitor medications like 
saqinavir (invirase), ritonavir (norvir) and indinavir (crixivan). Responses were 
also obtained for anti- infective medications like trimethoprim or 
sulfamethoxazole, clarithromycin, dapsone, flucanazole, rifabutin and 
itraconazole. It was a self-reported questionnaire. All the questionnaires were 
checked for completeness before the incentives were awarded. 
C. Measures and Variables assessed 
The questionnaire included questions regarding the following: 
• Demographics: age, gender, ethnicity, years of education, family income, 
health insurance coverage, number of people in the household, and 
employment status. 
• Current health status and mood status. 
• Social support: emotional, financial, physical support from family and friends . 
• Physical functioning: severity of bodily pain, number of days in bed in the 
past two weeks, number of hospitalizations in the past year, interference of 
pain with normal work in the past four weeks, T-cell count last tested. The 
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Medical Outcomes Study (MOS) 36 item quality of life scale was included 
(54). 
• Medical status: self reported disease and medication history, number of doses 
missed in the past one month, number of doses missed in the past three 
months. 
• Coping: ways in which people cope with HIV and its treatment. The Ways of 
coping scale as modified by Dunkel-Schetter, Feinstein, Taylor, Flake (53) to 
suit their study on cancer patients was included. 
D. Assessment of Medication Adherence 
Medication adherence with anti-retroviral and protease inhibitor medications was 
assessed separately using data on two scales. The adherence was calculated 
separately for antiretroviral and protease inhibitor medications because the 
respondents had answered questions for each type of medication separately. The 
two scales used to measure adherence are: 
1. Medication Adherence Scale: MAS or Medication Adherence Scale is a 
previously validated scale to measure adherence (55). It contains six questions 
that are answered yes or no. A positive response indicates inadequate 
adherence. 
• During the last 3 months, have you ever stopped taking your antiretroviral 
medication because you felt worse? 
• During the last 3 months, have you ever forgotten to take antiretroviral 
medication? 
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I • During the last 3 months, have you at times been careless about taking 
antiretroviral medication? 
• During the last 3 months, have you ever taken less of your antiretroviral 
medicine than your doctor prescribed because you felt better? 
• During the last 3 months, have you ever taken less of your antiretroviral 
medicine than your doctor prescribed because you felt worse? 
• Since you began taking protease inhibitor/antiretroviral medication, have you 
ever purposely taken more/less of the medicine than your physician prescribed 
or discontinued your medication? 
On the response options, a "Yes" was coded as "2" and "No" was coded as "l ". 
The score for the scale was obtained by summing the response codes on each item 
on the scale. The range for the scales could thus be 6 to 12. Any respondents who 
had not responded to more than one item were dropped from the analyses. The 
scores were calculated separately for antiretroviral drugs and protease inhibitor 
drugs. The MAS score for each anti-retroviral drug was calculated. Further, the 
average score for all the anti-retroviral drugs was calculated and used in the 
analyses. Similarly, the scores for all protease inhibitor drugs were calculated and 
averaged. 
Percentage Adherence: 
Percentage adherence in the past one month was calculated using the answers to 
the questions "During the past month, about how many times did you miss a dose 
of the medication?" and "How often do you take this medication?" The responses 
to the question "How often do you take this medication" were used to determine 
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the total doses prescribed for each medication. From this question, the number of 
doses the respondent should take for one month was calculated. 
Percentage adherence in the past one month was calculated using the formula: 
Percentage adherence = 
Number of doses of 
1- medication missed in the past one month x 100 
Total number of doses 
in the past one month 
The percentage adherence in the past one-month was determined separately for 
antiretroviral drugs and protease inhibitors. Protease inhibitor medications were 
newly introduced at the time of the study, and hence it was thought interesting to 
explore adherence to these drugs separately. The percentage adherence was 
calculated for all the antiretroviral drugs and was averaged to get an average 
percentage adherence in the past one month to all antiretroviral medications the 
patient was on. Similarly, the percentage adherence was determined for all 
protease inhibitors and was averaged. Thus, the range of values for percentage 
adherence can be from 0 to 100. 
Two definitions were followed to classify respondents as adherent or non-
adherent. A respondent was classified as "adherent" if his percentage adherence 
was 100, i.e. he reported not missing any dose in the past one month. This 
stringent cut off was chosen to offset the likely overestimation of adherence by 
respondents. A big drawback of self-reported adherence is that the patients tend to 
overestimate the adherence (23,24). All the respondents having less than 100 % 
adherence were classified as "non-adherent". But since in the real world, it would 
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( be almost impossible to attain 100% adherence, an alternative cut off of 95% was 
also chosen. 
For the second cut-off, all patients showing 2:95% adherence were classified as 
"adherent" and those showing <95% adherence were classified as "non-adherent". 
This cut off was chosen based on a study by Paterson D et al. (14) that reported 
that even with adherence as high as 95%, only 80% of patients had undetectable 
viral loads. The coding system followed was: "1" for adherence, and "O" for non-
adherence. 
Coping: Coping was assessed using the responses to a 50-item scale. The scale 
gives the frequency of use of each coping style by the respondents. The questions 
were of the type: In the last month, how often did you think, feel or do each item? 
The response options to the items are in form of a likert scale as follows: 
1 =Never; 2= Rarely; 3=0ccasionally; 4= Often; 5= Very often 
This scale was taken from the Ways of Coping Questionnaire (WOC) developed 
by Folkman and Lazarus (44). It describes a broad range of behavioral and 
cognitive coping strategies that a person might use during a stressful encounter. 
This scale was revised by Lazarus, Folkman, Dunkel-Schetter to develop a 
questionnaire with 51 items. This scale was again modified by Dunkel-Schetter, 
Feinstein, Taylor, Flake (53) to suit their study on cancer patients. These were the 
first coping patterns to be identified with a large and heterogeneous sample of 
cancer patients and they are similar to those identified with a large sample of 
community residents experiencing a variety of life stressors. It appears that they 
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may be representative of universal dimensions of coping. The five factors 
developed as a result of factor loadings were: 
Behavioral Escape- Avoidance: sum of nine items (item numbers 29, 23, 24, 35, 
39, 18, 3, 5, 25). 
Focus on positive: sum of eight items (item numbers 26, 27, 17, 41, 21, 28, 14, 
47). 
Distancing: sum of 12 items (item numbers 40, 30, 33, 9, 10, 11, 50, 37, 15, 32, 
48, 52). 
Cognitive-Escape-Avoidance: sum of nine items (item numbers 7, 44, 45, 42, 
43, 46, 8, 51, 12). 
Seek and Use Social Support: sum of eleven items (item numbers 4, 34, 22, 20, 
16, 49, 13, 31, 6, 19, 1). 
Description of these items is in appendix ill. 
The final score for each factor was obtained by summing the responses on the 
items constituting that factor. Lazarus and Folkman (44) described this method of 
raw sconng. 
For example, the score for Behavioral Escape-Avoidance= Sum (qvi29 + qvi23+ 
qvi24+ qvi35+ qvi39+ qvi18+ qvi5+ qvi3+ qvi25) 
For each factor, observations with more than two missing values were dropped 
from the analyses. 
E. Variables Used: 
The following variables were determined to be of interest and were included in 
the analyses. 
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Dependent Variables: 
1. Percentage adherence: to antiretroviral drugs in the past one-month. (100% 
as cut off)- abbreviated as 100% A.V. 
2. Percentage adherence: to antiretroviral drugs in the past one-month. (95% as 
cut off)- abbreviated as 95% A.V. 
3. Percentage adherence: to protease inhibitor drugs in the past one-month. 
(100% as cut off)-abbreviated as 100% P.I. 
4. Percentage adherence: to protease inhibitor drugs in the past one-month. 
(95% as cut off) -abbreviated as 95% P.I. 
5. Medication Adherence Scale for antiretroviral drugs: Dichotomous 
measure of adherence- abbreviated as MAS A.V. 
6. Medication Adherence Scale for protease inhibitor drugs: Dichotomous 
measure of adherence- abbreviated as MAS P.I. 
Independent Variables: 
The IV's of primary interest were the coping styles. These were used as 
continuous variables for univariate and bivariate analysis, but had to be 
categorized for use in final logistic regression analysis. The coping styles are: 
Seeking social support - abbreviated as 'sss'. 
Distancing -abbreviated as 'dis' 
Focusing on positive- abbreviated as 'fop' 
Behavioral escape avoidance -abbreviated as 'bea' 
Cognitive escape avoidance -abbreviated as 'cea' 
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Demographic Variables 
Age: The variable age was categorized into three groups of< 35 years, 35-41 
years and 2: 42 years. The first category was coded as 0, the 35-41 years age 
category was coded as 1, while the > 42 years age group was coded as 2 for the 
analysis. 
Gender: For the purpose of analysis, males were coded as '1' and females as 'O'. 
Race: The variable race was dichotomized into 'whites' and 'non-whites'. The 
'whites' were coded as 'l ', whereas 'native Americans', 'Hispanics', 'African 
American, 'Asian' and others' were collapsed into a single category 'non-whites' 
and were coded '0'. 
Annual income: The respondents were dichotomized as having income of less 
than $15,000 (coded as' 1 '),or more than$ 15,000 (coded as 'O'). 
Years of Education: Respondents having attained more than 12 years of 
education were coded as 'O' where as those with less than 12 years of education 
were coded as ' 1 '. 
Insurance: The respondents which reported having any form of insurance were 
coded as 'O', where as those without any insurance were coded as '1 '. 
Clinical variables 
Bodily pain: Respondents who reported moderate to severe bodily pain were 
grouped into one category and were coded as '1 ', where as those which reported 
none to mild pain were coded as 'O'. 
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Times since diagnosis with HIV: Patients who had been diagnosed with HIV 
before less than 2 years were coded as '1 ', those diagnosed before 3-4 years were 
coded as '2', whereas those who were diagnosed before 5 years were coded as '3'. 
CD4 count: The patients with CD4 cell count between 50-200 were coded as 'O', 
whereas those with count between 201-500 were coded as '1 '. 
Injection drug use: Occasional and regular drug users were coded as '1 ', while 
those who were not drug users were coded as 'O'. 
There were 13 7 respondents who were prescribed antiretroviral medications. 
There were 77 respondents who were prescribed protease inhibitor medications. 
Data Analysis: 
The above-mentioned variables constitute the independent and dependent 
variables as described. The associations between the independent variables and 
the dependent variables were examined using bivariate and multivariate statistics. 
The data was analyzed using the Statistical Analysis System (SAS) version 8.00 
on the computers of Department of Applied Pharmaceutical Sciences, University 
of Rhode Island. 
The data was screened for normality, linearity and homoscedasticity. The variable 
"adherence using MAS" was markedly negatively skewed for both antiretroviral 
medications and protease inhibitor medications. Several transformations including 
square root, exponential, log, were tried to make the variable normal. The variable 
was dichotomized due to a markedly skewed distribution. All respondents with a 
score of 6 were categorized as being "adherent" and those with score of 7 and 
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above were categorized as being "non-adherent", that is, any respond who 
responded 'yes' to even a single question were categorized as being non-adherent. 
Further, bivariate analyses were run between the primary independent variables 
and all other variables and also between the primary dependent variables and all 
other variables to check for the potential confounding variables. Bivariate 
statistics were used to determine the association between each dependent variable 
and each independent variable, excluding the independent variables of primary 
interest i.e. copmg styles. Similarly, association between each primary 
independent variable and other independent variables was determined. The 
associations between each dependent variable (100% A.V., 95% A.V., 100% P.I., 
95% P.I., MAS A.V., MAS P.I.) and the independent variables (age, gender, race, 
income, years of education, insurance, bodily pain, time since diagnosis, CD4 
count, injection drug use) excluding the primary independent variables, i.e. the 
coping styles, were explored using chi-square tests. The associations between 
each primary independent variable (sss, dis, fop, bea, cea) and other independent 
variables (gender, race, income, years of education, insurance, bodily pain, CD4 
count, injection drug use) were explored using multiple T-tests. ANOVA's were 
run to explore the association between the coping styles (ss, dis, fop, bea, cea) and 
the variables "time since diagnosis" and "age". 
Further, each primary independent variable (coping styles) was categorized into 
three categories so that preliminary logistic regression models could be run 
between each coping style and each dependent variable to assess the parametric 
form. The primary independent variables were transformed into categorical 
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variables as they did not show a linear relationship with the dependent variables 
and hence could not be used as continuous variables in the final logistic models. 
Each coping style was categorized into three level variables based on the 
frequency distribution. Each coping style was categorized as "seldom used", 
"used often" and "used very often". Further, these categorical independent 
variables were transformed into dummy variables as follows: 
Seeking Social Support: 
ssshigh- 'using seeking social support very often' 
sssmed- 'using seeking social support often 
reference category- 'using seeking social support seldom' 
Distancing: 
dishigh- 'using distancing very often' 
dismed- 'using distancing often 
reference category- 'using distancing seldom' 
Focusing on Positive: 
fophigh- 'using focusing on positive very often' 
fopmed- 'using focusing on positive often 
reference category- 'using focusing on positive seldom' 
Behavioral Escape Avoidance: 
beahigh- 'using behavioral escape avoidance very often' 
beamed- 'using behavioral escape avoidance often 
reference category- 'using behavioral escape avoidance seldom' 
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.. 
Cognitive Escape Avoidance: 
ceahigh- 'using cognitive escape avoidance very often' 
ceamed- 'using cognitive escape avoidance often 
reference category- 'using cognitive escape avoidance seldom' 
The variable 'age' was dummy coded as follows: 
highage- >=42 years. 
medage- 35-41 years. 
reference category- < 35 years. 
The variable 'time since diagnosis' was dummy coded as follows: 
longtime- >= 5 years. 
medtime- 3 to 4 years. 
reference category- <=2 years. 
Finally, logistic regression analysis was run to assess the effect of each coping 
style on each dependent variable. Logistic models were run separately for each 
independent variable with each dependent variable. Logistic regression models to 
assess the effect of each primary independent variable on each dependent variable 
were tested following the strategy described by David Kleinbaum. The 'chunk' 
tests were performed to detect any interactions. The Maximum Likelihood ratio 
tests were used to check for the significance of the interaction terms in the model. 
The likelihood ratio test is a chi-square test that makes use of maximum 
likelihood values. The full model with the interaction terms included and the 
reduced model (without interaction terms) were compared using the difference 
between the log likelihood statistics for the two models. Checking the effect of 
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adding each variable to the model separately assessed confounding. Confounding 
assessment followed the interaction assessment. The confounding assessment was 
guided by considerations of validity and precision as described by Klienbaum. 
Starting with the 'gold model', i.e. the model with all Independent variables 
included, variables were sequentially dropped to check the effect on the odds 
ratios and 95% confidence intervals. Only the variables whose deletion did not 
caused a change in the odds ratio and C.I. were dropped. Separate models were 
run for each primary independent variable due to high correlation between them. 
Each primary independent variable was conceptually very different and separate 
models were run to assess the effect of each primary l.V. on each D.V. 
The logistic regression models are listed below: 
For Anti-retroviral drugs: 
1) Percentage adherence 100% cut-off (D.V.)= ssshigh + sssmed 
2) Percentage adherence 100% cut-off (D.V.)= dishigh + dismed 
3) Percentage adherence 100% cut-off (D.V.)= fophigh + highmed 
4) Percentage adherence 100% cut-off (D.V.)= beahigh +beamed 
5) Percentage adherence 100% cut-off (D.V.)= ceahigh + ceamed 
6) Percentage adherence 95% cut-off (D.V.)= ssshigh + sssmed 
7) Percentage adherence 95% cut-off (D.V.)= dishigh + dismed 
8) Percentage adherence 95% cut-off (D.V.)= fophigh + highmed 
9) Percentage adherence 95% cut-off (D.V.)= beahigh +beamed 
lO)Percentage adherence 95% cut-off (D.V.)= ceahigh + ceamed 
11) MAS adherence (D. V)= ssshigh + sssmed 
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12) MAS adherence (D.V)= dishigh + dismed 
13) MAS adherence (D.V)= fophigh + highmed 
14) MAS adherence (D.V)= beahigh +beamed 
15) MAS adherence (D. V)= ceahigh + ceamed 
For protease-inhibitor drugs: 
16) Percentage adherence 100% cut-off (D.V.)= ssshigh + sssmed 
17) Percentage adherence 100% cut-off (D.V.)= dishigh + dismed 
18)Percentage adherence 100% cut-off(D.V.)= fophigh + highmed 
19) Percentage adherence 100% cut-off (D.V.)= beahigh +beamed 
20) Percentage adherence 100% cut-off (D.V.)= ceahigh + ceamed 
21)Percentage adherence 95% cut-off(D.V.)= ssshigh + sssmed 
22) Percentage adherence 95% cut-off (D.V.)= dishigh + dismed 
23) Percentage adherence 95% cut-off (D.V.)= fophigh + highmed 
24) Percentage adherence 95% cut-off (D.V.)= beahigh +beamed 
25)Percentage adherence 95% cut-off(D.V.)= ceahigh + ceamed 
26) MAS adherence (D.V)= ssshigh + sssmed 
27) MAS adherence (D.V)= dishigh + dismed 
28) MAS adherence (D.V)= fophigh + highmed 
29) MAS adherence (D.V)= beahigh +beamed 
30) MAS adherence (D.V)= ceahigh + ceamed 
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RESULTS 
Table 1. Demographics and Clinical Characteristics of Patient Population 
prescribed Anti-retroviral Medication: 
A total of 137 patients were on anti-retroviral medication. These patients were 
between the ages of 24 to 57. The median age was 38. An equal proportion of 
respondents (34.09%) were between the age groups of 35-41 years and greater 
than 42 years, where as 31.82% were less than 35 years of age. The majority of 
the patients were males, who constituted 72.06% of the sample, whereas females 
constituted 27.94% of the sample. 
A majority of the respondents (65.18%) had more than 12 years of education. 
72.99% of the sample reported that their health status was excellent to good. 
Whites constituted 63.50% of the sample, while the non-whites (Native 
Americans, Hispanics, Asians, African Americans and others) constituted 36.50% 
of the sample. About 29.20% of the patients said that they lived alone, while 
70.80% said that they lived with others. 61.24% of the patients reported that their 
annual income was less than $15,000, while 38.76% reported that their annual 
income was above $15,000. Only 16.06% of the patients reported as having no 
insurance, while 83.74% reported as having some insurance.59.85% of the 
patients reported that they experienced none to mild bodily pain, while 40.15% 
reported that they experienced moderate to very severe bodily pain. 64.18% of the 
patients reported that they had been diagnosed with HN for a time period greater 
than 5 years. 47.92% of the patients reported that their T-cell count was less than 
200 and 53.08% of the patients reported that their T-cell count was greater than 
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200. Only 3.65% of the patients reported that they occasionally used intravenous 
drugs, while the majority of the patients, 40.88% reported that they had never at 
all or never in the past 6 months used intravenous drugs. 
Table 2. Demographics and clinical characteristics of patient population 
prescribed Protease-inhibitor medication: 
A total of 76 patients were on protease-inhibitor medication. These patients were 
between the ages of 24 to 57. The median age was 38. Of these, 40% were above 
42 years, 36% between 35-41 years and 24% below 35 years of age. The majority 
of the patients were males, who constituted 75.00% of the sample, whereas 
females constituted 25.00% of the sample. A majority of the respondents 
(77.33%) had more than 12 years of education. 80.52% of the sample reported 
that their health status was excellent. Whites constituted 75.32% of the sample, 
while the non-whites (Native Americans, Hispanics, Asians, African Americans 
and others) constituted 24.68% of the sample. About 28.57% of the patients said 
that they lived alone, while 71.43% said that they lived with others. 57.33% of 
the patients reported that their annual income was less than $15,000, while 
42.67% reported that their annual income was above $15,000. Only 12.99% of the 
patients reported as having some insurance, while 87.01 % reported as having no 
insurance.58.44% of the patients reported that they experienced none to mild 
bodily pain, while 41 .56% reported that they experienced moderate to very severe 
bodily pain. 59.74% of the patients reported that they had been diagnosed with 
HIV for a time period greater than 5 years. 51.33% of the patients reported that 
their T-cell count was less than 200 and 48.65% of the patients reported that their 
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T-cell count was greater than 200. Only 2.60% of the patients reported that they 
occasionally used intravenous drugs, while the majority of the patients, 41.96% 
reported that they had never at all or never in the past 6 months used intravenous 
drugs. 
Table 3. Adherence with Anti-retroviral (A.V.) and Protease Inhibitor (P.I.) 
Medications (Dependent Variables): 
For patients on A.V Medications: With a 95% cut off (patients whose adherence 
was above 95% were categorized as adherent, while those below 95% were 
categorized as non-adherent), 85.61 % (n = 113) of the patients were found to be 
adherent, whereas 14.39% (n = 19) were found to be non-adherent. 
With a 100% cut off (patients whose adherence was 100% were categorized as 
adherent, while those below 100% were categorized as non-adherent), 47.73% (n 
= 63) of the patients were found to be adherent whereas 52.27% (n = 69) were 
found to be non-adherent. 
Using the MAS, 45.26% (62) patients were found to be adherent, while 54.74% 
(75) patients were found to be non-adherent. 
For patients on P.I Medications: With a 95% cut off (patients whose adherence 
was above 95% were categorized as adherent, while those below 95% were 
categorized as non-adherent), 86.67% (n = 65) of the patients were found to be 
adherent whereas 13.33% (n = 10) were found to be non-adherent. 
With a 100% cut off (patients whose adherence was 100% were categorized as 
adherent, while those below 100% were categorized as non-adherent), 49.33% (n 
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( = 37) of the patients were found to be adherent whereas 51.95% (n = 40) were 
found to be non-adherent. 
Using the MAS, 48.05% (37) patients were found to be adherent, while 51.95% 
( 40) patients were found to be non-adherent. 
Table 4. Frequency of use of each coping style (primary I.V.) by patients 
prescribed Anti-retroviral and those prescribed Protease Inhibitor 
Medications: 
For patients on A.V. Medications: Patients were categorized into three groups 
based on the frequency of use of the coping styles i.e. using coping style seldom, 
using it often and using it very often. The majority (43.31%) of the patients 
reported using "Focusing on positive" very often. Seeking social support, 
distancing, Behavioral escape avoidance, cognitive escape avoidance and was 
used very often by 35.43%, 38.89%, 40.00%, and 38.40% patients respectively. 
For patients on P.I. Medications: Majority (44.59%) of the patients reported 
using "Focusing on positive" very often. Seeking social support, distancing, 
Behavioral escape avoidance, cognitive escape avoidance and was used very often 
by 44.00%, 43 .24%, 40.85%, and 44.59% patients respectively. Thus there is no 
trend or preference for use of any particular coping style by patients. 
Table 5: Adherence status by frequency of use of coping style in patients on 
Antiretroviral medications: Table 5 summarizes the adherence status of patients 
on antiretroviral medication by their frequency of use of coping styles. The results 
are comparable for 100% adherence and adherence as measured by MAS. 
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( Table 6: Adherence status by frequency of use of coping style in patients on 
Protease inhibitor medications: Table 5 summarizes the adherence status of 
patients on protease inhibitor medication by their frequency of use of coping 
styles. 
Table 7. Multiple Chi-Square Tests with Adherence to Antiretroviral 
Medications with 100% cut off (Categorical Dependent Variable) and other 
Categorical Independent Variables: 
None of the independent variables was significantly associated with adherence in 
the chi square test. 
Table 8. Multiple Chi-Square Tests with Adherence to Antiretroviral 
Medications with 95% Cut-off (Categorical Dependent Variable) and other 
Categorical Independent Variables: 
None of the variables showed a significant association with medication 
adherence. The variables "insurance" and "time since diagnosis" did not have 
enough sample size per cell and hence the chi-square was not a valid test to check 
for the differences in the proportions of respondents who were adherent and those 
who were non-adherent. 
Table 9. Multiple Chi-Square Tests run with Adherence to Antiretroviral 
Medications using MAS (Categorical Dependent Variable) and other 
Categorical Independent Variables: 
None of the variables showed a significant difference in their proportions of 
adherent and non-adherent patients, suggesting no association between these 
variables and adherence. 
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( Table 10. Multiple Chi-Square Tests with Adherence to Protease inhibitor 
Medications with 100% cut off (categorical Dependent Variable) and other 
Categorical Independent Variables. 
The variable "gender" (p= 0.02) was found to be significantly different between 
the adherent and non-adherent patients. Greater proportion of males were 
adherent. 
Table 11. Multiple Chi-Square Tests with Adherence to Protease Inhibitor 
Medications using MAS (categorical Dependent Variable) and other other 
Categorical Independent Variables: 
The variables "annual family income"(fisher's p value= 0.16), "T-cell count" (p-
value = 0.03) were found to be significantly different between the adherent and 
non-adherent patients. Respondents with annual income more than $15,000 and 
those with T-cell count of less than 200 were found to be more adherent than 
those with income less than $15,000 and those with T-cell count greater than 200. 
Table 12. Multiple T tests with "Seeking social support" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed anti-retroviral medication: 
The mean score on the variable "Seeking Social Support" was significantly 
different between the patients with insurance and patients with no insurance (p-
value=0.0003). The mean score was also significantly different between patients 
living alone and patients living with someone (p-value=0.005). The patients who 
were insured and those who lived alone had greater mean score on "Seeking 
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Social Support" as compared to those who were uninsured and those who did not 
live alone. 
Table 13. Multiple T tests with "Distancing" (Continuous primary l.V.) and 
other Independent Variables (Categorical) for people prescribed anti-
retroviral medication: 
The mean score on the variable "Distancing" was significantly different between 
the patients living alone and patients not living alone (p-value=0.03). The patients 
living alone had a greater mean score on the variable "Distancing" as compared to 
those who did not live alone. 
Table 14. Multiple T tests with "Focusing on Positive" (Continuous primary 
I.V.) and other Independent Variables (Categorical) for people prescribed 
an ti-retroviral medication: 
The mean score on the variable "Focusing on Positive" was significantly different 
between the patients with excellent/good health and patients with fair/poor health 
(p-value=0.03). The score was also significantly different between the patients 
living alone and those not living alone (p-value=0.05). Also, the mean score was 
significantly different between patients with income <15,000 and those with 
income 2: 15,000 (p-value=0.02). 
Table 15. Multiple T tests with "Behavioral Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed anti-retroviral medication: 
The mean score on the variable "Behavioral Escape Avoidance" was significantly 
different between the patients living alone and those not living alone (p-
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value=0.03). The score was also significantly different between the patients with 
none/mild pain and patients with moderate/severe pain (p-value=0.01). The 
patients living alone and those with moderate to severe pain reported more 
behavioral escape avoidance as compared to patients not living alone and those 
with none to mild pain. 
Table 16. Multiple T tests with "Cognitive Escape Avoidance" (Continuous 
primary l.V.) and other Independent Variables (Categorical) for people 
prescribed anti-retroviral medication: 
The mean score on the variable "Cognitive Escape Avoidance" was significantly 
different between the white patients and the non-white patients (p-value=0.01). 
Whites had a significantly greater score on cognitive escape avoidance scale as 
compared to the non-whites. 
Table 17. ANOVA between the categorical l.V "Time Since Diagnosis", 
"age" and continuous primary Independent Variables for people prescribed 
An ti-retroviral medication: 
None of the continuous primary I.V's showed significant differences across the 
groups of "time since diagnosis" or "age". 
Table 18. Multiple T tests with "Seeking social support" (Continuous 
primary l.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medication: 
The mean score on the variable "Seeking Social Support" was significantly 
different between the patients with insurance and those without insurance (p-
value=0.002). The scores were also different between patients with none/mild 
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body pain and those with moderate/severe pain (p-value=0.03). The patients with 
some insurance and those with moderate to severe pain reported using more 
seeking social support as compared with those with no insurance and those with 
none to mild pain. 
Table 19. Multiple T-tests with "Distancing" (Continuous primary l.V.) and 
other Independent Variables (Categorical) for people prescribed Protease-
inhibitor medications: 
No significant difference was found in the means of the variable "distancing". 
Table 20. Multiple T-tests with "Focusing on Positive" (Continuous primary 
1.V.) and other Independent Variables (Categorical) for people prescribed 
Protease-inhibitor medications: 
The mean score on the variable "focusing on positive" was significantly different 
between the patients with insurance and those without insurance (p-value=0.04). 
The patients with some insurance reported using focusing on positive as 
compared to those with no insurance. 
Table 21. Multiple T-tests with "Behavioral Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medications: 
The mean score on the variable "behavioral escape avoidance" was significantly 
different between the patients living alone and those not living alone (p-
value=0.008). 
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Table 22. Multiple T-tests with "Cognitive Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medications: 
No significant difference was found in the means of the variable "Cognitive 
Escape Avoidance". 
Table 23. ANOV A between the Categorical Independent Variable "Time 
since diagnosis", "age" and Continuous primary Independent Variables for 
People prescribed Protease-inhibitor Medications: 
There was significant difference in the means of the variable "Cognitive Escape 
Avoidance" between the groups of variable "time since diagnosis" (p-value=0.02) 
for people prescribed A.V. medications. 
The results for patients on P.I. medications were non significant. 
Table 24 to Table 47 summarize the final logistic regression models run between 
each of the independent variables (coping styles) with each of the dependent 
variables (100% A.V. , 95% A.V., MAS A.V., 100% P.I. , 95% P.I., MAS P.I.) 
controlling for the potential confounding variables. In the bivariate tests, some 
demographic and clinical variables were found to be significantly associated with 
either some independent variable or some dependent variable, but none was found 
to be significantly associated with both the independent variable and dependent 
variable, and hence did not qualify to be a confounder. Introducing the variables 
in ascending order as well as descending order assessed the effect of each 
independent variable on the dependent variables. In the final model, 'behavioral 
escape avoidance' was significantly associated with medication adherence as 
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( assessed by medication adherence scale for patients on antiretroviral medications. 
The people who used behavioral escape avoidance very often are 60% less likely 
to be adherent as compared to those who use this coping style seldom. Similarly, 
people who used behavioral escape avoidance often are 70% less likely to be 
adherent as compared to those who use this coping style seldom. BEA was also 
significantly associated with adherence to antiretroviral medications using a 100% 
cut off definition. The respondents using BEA very often are 70% less likely and 
those using BEA often are 90% less likely to be adherent as compared to their 
counterparts who use BEA seldom. All other logistic regression models were non-
significant. Also, the final models revealed some interesting associations. 
Education and living arrangement were also found to be significantly associated 
with adherent to protease inhibitors as defined by 95% cut off. The respondents 
with less than 12 years of education and those living alone were 90% less likely to 
be adherent as compared with those with more than 12 years of education and not 
living alone. 
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Discussion 
The purpose of this research was to assess coping with HIV as a predictor of 
medication adherence. Two measures of medication adherence, MAS and 
percentage adherence were used to assess the adherence to anti-retroviral and 
protease-inhibitor medications. There is much uncertainly as to what definition or 
method is best for measuring and assessing medication adherence. Hence, 
classifying the respondents as being adherent or non-adherent was accomplished 
using two scales to increase the validity. Both the scales gave data which was 
self-reported by the patients. Two cut-offs were used for the percentage 
adherence, 95% cut-off and 100% cut off. The 95% cut-off was chosen based on 
literature review. The 100% adherence cut off, though seemingly unpractical, was 
chosen because it has been well established how medication adherence dictates 
the success of the medication therapy in HIV. It is absolutely imperative to adhere 
strictly to the medication regimen. Given the repercussions of non-adherence and 
missing even a few doses, strict adherence with the medication regimen is 
imperative. Efforts should be directed to have the most stringent benchmark for 
adherence, to identify the factors influencing and predicting adherence, and to use 
this knowledge to develop dedicated interventions to eradicate the problem of 
non-adherence. Disease states affect not only physical health, but also have 
psychological implications. This is especially true in diseases like HIV, which has 
no cure as yet, and leads to a slow death. The complexities of this disease are 
enormous as it raises concerns regarding health, well-being, and social stigma, 
confounded by a slow and sure death. Hence it is necessary to study the 
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psychological factors that may influence various factors and behaviors, including 
medication adherence. Coping is one such psychological domain that has not been 
studied in relation to medication adherence in depth. Research with psychological 
variables is complicated by the fact that there are no standard tools for 
measurement of the domains. For this study, responses on the Ways of Coping 
Questionnaire as modified by Dunkel-Schetter were used. In this study, most 
patients coped in multiple ways with HIV. Patients did not report any single 
pattern of coping more frequently than the other. This is consistent with the 
results of the study by Dunkel-Schetter et al. in which they determined the coping 
strategies used by cancer patients (53). The patients appear to use a large 
repertoire of behaviors to cope flexibly with HIV, rather then rigidly adhering to a 
particular coping style. This indicates to instability in the pattern of use of coping 
styles. Lazarus and Folkman opine that coping strategies used keep changing 
based on changing appraisal of stress level and situation. This situational aspect 
and changing instable nature of coping makes assessment of coping styles a 
difficult issue. Some authors have suggested measuring coping responses over 
time and exploring sustainable trends over time. 
For the patients prescribed protease inhibitors, males exhibited significantly 
more adherence than females, using the percentage cutoff definition of adherence. 
Gender has been inconsistently associated with medication adherence with HIV in 
previous research. HIV+ women have also been shown to be more depressed than 
males (56). This could have a bearing on adherence. In a retrospective cohort 
study of antiretroviral medication adherence using New York State Medicaid 
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( data, women were less likely to be adherent and more likely to be depressed than 
males (56). In a study to characterize the prevalence and predictors of diagnosed 
depression among HIV patients on Medicaid, women were more likely to be 
diagnosed with depression (57). The respondents who reported living alone 
displayed significantly low adherence as compared to those not living alone. This 
could be attributed to the important role social support plays in adherence 
behavior. Previous research has demonstrated consistently that patient with good 
social support display better adherence to medical therapy. This may be due the 
support, care and reminders from the people living with the patients. Similarly, 
those with education greater than 12 years are significantly more adherent as 
compared with those with less than 12 years of education. Education imparts a 
maturity and sense of responsibility. People with more education may be more 
capable of understanding the disease and the importance of adherence better. Also 
educated people may have more income as compared with those who are not 
educated. Similarly, when adherence was assessed using MAS, patients with 
greater family income were found to be significantly more adherent as compared 
to those with low income. This could be because these patients are able to better 
afford the medications. In the literature review, demographic variables have been 
reported to be inconsistently associated with medication adherence. This 
variability is rooted in the varied samples, varied definitions of adherence and 
different measurement techniques. Some significant associations were observed 
. 
with the styles of coping used. Patients with some insurance and those with 
moderate to sever pain reported using ' seeking social support' with significantly 
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( 
greater frequency as compared with those having no insurance and with mild 
pain. This could be because patients with insurance could have more meaningful 
social interactions and those in pain and suffering have a tendency to seek 
external support. Patients with some insurance were also found to use 'focusing 
on positive' to a significantly greater extent than those with no insurance. 
In the final logistic regression models, the variable gender was significantly 
associated with percentage adherence using the 100% cut off (OR, 0.2; 95% Cls, 
0.08-0.8). Males were 80% less likely to be adherent to protease inhibitors as 
compared with females. In the previous researches, gender has been inconsistently 
associated with medication adherence. 
For patients prescribed antiretroviral medications, those with some insurance 
coverage and those living alone used 'seeking social support' with significantly 
greater frequency as compared with those with no insurance and not living alone. 
Also, patients living alone reported significantly more use of 'distancing' and 
'behavioral escape avoidance' as compared with patients not living alone. This 
could be because people who use passive coping strategies tend to be more 
depressed and withdrawn. Patients having some insurance, those with good 
health, living alone and having income greater than $15,000 reported using 
'focusing on positive' significantly more than those without these attributes. With 
the knowledge of these associations, people with the attributes associated with 
non-adherent can be identified and targeted for interventions. 
Coping- the results of this study indicate the coping style 'behavioral escape 
avoidance', was significantly associated with adherence to antiretroviral 
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( medications as assessed by the medication adherence scale and 100% cut-ff. 
Consistent with the results of previous research which assess effect of coping 
strategies on various outcomes, behavioral escape avoidance seems to have an 
inverse effect with medication adherence as assessed by medication adherence 
scale in patients prescribed antiretroviral medications. Behavioral escape 
avoidance is known to involve behavioral signs of avoidance such as social 
withdrawal, impulsivity and drug use. The patients who use this coping style very 
often and often are 80% and 90% less likely to be adherent as compared to those 
who seldom use behavioral escape avoidance. Use of behavioral escape avoidance 
was found to be significantly associated with percentage adherence to 
antiretroviral drugs using the 100% cut off. The patients who use this coping style 
'very often' and 'often' are 70% and 90% less likely to be adherent as compared 
to those who seldom use behavioral escape avoidance This result is in agreement 
with that obtained by Singh et al. ( 49) in a study of predictors in a sample of 123 
HIV+ patients. Singh et al. used the Billings and Moos coping inventory to assess 
the active-cognitive, active-behavioral or avoidance coping used by the 
respondents. The results showed that 'avoidance' coping was significantly 
correlated with non-adherence. Avoidance coping involved strategies like denying 
that the problems exists, or indirectly reducing tension by behaviors like eating 
and smoking. These strategies are very similar to those that constitute behavioral 
escape avoidance in this study. Adherence was measured by refill adherence and 
patients who obtained <90% or refills in the preceding six months were 
considered non-adherent. In a prospective study involving 46 patients, Singh et al. 
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( (19), utilized the 'Ways of coping questionnaire' to assess coping styles and their 
association with medication refill adherence at 6 months. The authors reported 
that adherence was significantly associated with better adaptive coping and non 
adherence with poor coping. Although in this research no association was found 
between adaptive coping styles like seeking social support or focusing on 
positive, non-adherence was significantly associated with behavioral escape 
avoidance. Although the previous researchers have used different coping scales 
for assessing coping as predictor of medication adherence, the coping behaviors 
involving escape avoidance strategies have consistently been associated with non-
adherence. 
This indicates that patients who exhibit behavioral escape avoidance tend to be 
less adherent and is a group, which should be focused for behavioral intervention. 
The conceptualization of adherence as the extent to which the patient follows 
medical instructions is an oversimplification of a multidimensional complex 
construct. It is now agreed upon that adherence is the extent to which a patient's 
behavior- taking medications, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from health care provider (58). 
Adherence involves a motivated behavioral change. This broader view of 
adherence highlights the importance of psychological constructs and predictors of 
adherence. This study is an addendum to and compelling support to the previous 
researches that have investigated psychological predictors to adherence. The 
results obtained are within some limitations, which despite diligence in statistical 
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methodology, could have contributed significantly to the results. These limitations 
are discussed in the following paragraph. 
Limitations: The limitations, in part were due to the nature of the data and also 
the lack of reliable and foolproof measures for the variables such as medication 
adherence. 
The sample size was only 145. Many variable distributions were skewed. 
Statistical techniques were used to rectify this shortcoming, but the skewness may 
indicate selection bias. 
Self-reported data: A major shortcoming was the fact that the data was self-
reported. The validity of self-reports is questionable as it lends itself to patient's 
recollection of the past. Recall bias plagues self-reports. There is a degree of 
subjectivity that seeps in as the responses depend on the situational mood of the 
respondent, education, social desirability concerns. These might influence the 
patient's ability and willingness to give accurate responses. 
Measurement: The lack of any standard for the measurement and quantification 
of medication adherence is another limitation. The varied assessment techniques 
and definitions used for adherence and the varied results in adherence studies 
stand evidence to this. 
This study was an effort to work within these limitations and tries to assess coping 
as a predictor of medication adherence. More research with more objective 
measures needs to be carried out on a larger sample to make the results 
generalizable to the population. 
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CONCLUSION 
The study to assess coping as a predictor of adherence with HIV medication has 
produced some interesting results. For both anti-retroviral and protease-inhibitor 
medications, approximately 85% patients were adherent based on the 95% cut-off. 
This degree of adherence, though high is still inadequate in HIV. In contrast, the 
100% cut-off and MAS showed disappointing results . 50-55% of the patients 
were non-adherent on these scales. A majority of patients (43.31 %) on 
antiretroviral medications use "focusing on positive" very often. Majorities of the 
patients tend to use all coping styles very often. 
Contrary to expectations, the final logistic models were not significant, suggesting 
no association between coping styles and medication adherence. Only 'behavioral 
escape avoidance' was found to be significantly associated with adherence to 
antiretroviral medications when assessed using MAS and 100% cut off. This is 
consistent with previous research findings. Patients using avoidance strategies can 
be identified and targeted for behavioral interventions to improve adherence 
behavior. This association, however was not found with adherence using other 
measures like percentage cut offs. These results however, are from statistical 
manipulations of data on merely 145 patients. Moreover, the adherence was self-
reported. Measuring adherence is an extremely complex issue and self-reports are 
plagued by errors of overestimation and recall bias. The results obtained were 
within the limitations of limited sample size and self-reported adherence. Given 
the critical importance of adherence, focused efforts of identifying predictors of 
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( adherence usmg reliable and objective measures of adherence are essential. 
Psychological factors are important determinants of health, well-being and quality 
of life of patients. For a disease such as HIV, factors influencing medication 
adherence needs to be identified and evaluated to develop interventions that can 
solve the problem of non-adherence and help make maximum good of the 
therapies available. More research needs to be done on such factors, including 
cop mg. 
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( Appendix I- Result Tables 
Table 1: Demographics and Clinical Characteristics of Patient Population 
prescribed Anti-retroviral Medication: 
Demographic N(%) 
Variables 
Age Mean=39.24 
< 35 yrs. 42(31.82) Median=38 
35-41 yrs. 45(34.09) Min=24 MaX:=57 
'.:'.: 4 2 _}'!"_S. 45(34.09) S.D.= 7.55 
Yrs. of education Mean=12.00 
<12 yrs. 46(34.85) Median=12 
'.:'.: 12 yrs. 86(65.18) Min=O Max=22 
S.D.=3.04 
Gender 
Female 38(27.94) 
Male 98(72.06) 
Race 
Whites 87(63 .50) 
Non-whites: 50(36.50) 
-Native American 
-Hispanic 
-Asian 
-African American 
-Others 
Living arrangement 
Alone 40(29.20) 
With others 97(70.80) 
Annual Household 
Income 79(61.24) 
<1 5,000 50(38.76) 
> 15,000 
Insurance 
Some 22(16.06) 
None 115(83.74) 
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( Clinical Variables N(%) 
Bodily pain 
None-Mild 82(59.85) 
Moderate-V.Severe 55(40.15) 
Current Health Status 
Excellent-Good 100(72.99) 
Fair-Poor 37(27.01) 
Time Since Diagnosis 
<lmonth-2years 23(17.16) 
3-4 years 25(18.66) 
=::: 5 years 86(64.18) 
T-cell Count 
::::200 61(46.92) 
>200 69(53.08) 
IV Drug Use 
Never or not in past 6 56(40.88) 
months 
Occasionally 5(3.65) 
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Table 2: Demographics and Clinical Characteristics of Patient Population 
prescribed Protease-inhibitor Medication: 
Demographic N(%) 
Variables 
Age Mean=39.37 
< 35 yrs. 18(24.00) Median=38 
35-41 yrs. 27(36.00) Min=24 Max=57 
2: 42 yrs. 30(40.00) S.D.= 7.44 
Yrs. of education Mean=12.88 
<12 yrs. 17(22.67) Median=12 
2: 12 yrs. 58(77.33) Min=O Max=22 
S.D.=3.19 
Gender 
Female 19(25.00) 
Male 57(75.00) 
Race 
Whites 58(75.32) 
Non-whites: 19 (24.68) 
-Native American 
-Hispanic 
-Asian 
-African American 
-Others 
Living arrangement 
Alone 22(28.57) 
With others 55_.(71.43) 
Annual Household 
Income 43(57.33) 
<15,000 32(42.67) 
> 15,000 
Insurance 
Some 10(12.99) 
None 67(87.01) 
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Clinical Variables N(%) 
Bodily pain 
None-Mild 45(58.44) 
Moderate-V.Severe 32(41.56) 
Current Health Status 
Excellent-Good 62(80.52) 
Fair-Poor 15(19.48) 
Time Since Diagnosis 
<lmonth-2years 15(19.58) 
3-4 years 16(20.78) 
::: 5 years 4659.74) 
T-cell Count 
::::200 36(48.65) 
>200 38(51.35) 
IV Drug Use 
Never or not in past 6 32(41.56) 
months 
Occasional!Y_ 2(2.601 
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Table 3: Adherence with Anti-retroviral (A.V.) and Protease Inhibitor 
Medications (Dependent Variables): 
Dependent Variable Adherent Non-adherent 
Number_{%l Number_{%} 
Antiretroviral Medication 
AV. 95% cut-off 113 (85.61) 19 (14.39) 
AV. 100% cut-off 63 (47.73) 69 (52.27) 
MAS Adherence 62(45.26) 75(54.74) 
Protease Inhibitor Medication 
P .I. 95% cut-off 65 (86.67) 10 (13 .33) 
P.I. 100% cut-off 37 (49.33) 38 (50.67) 
MAS Adherence 37(48.05) 40(51 .95) 
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( Table 4: Frequency of use of each coping style (primary I.V.) by patients prescribed Anti-retroviral and those prescribed Protease Inhibitor 
Medications: 
Coping style Seldom Often Very 
N(%) N(%) often 
N_{_%l 
Patients Prescribed Antiretroviral Medications: 
Seeking Social 36 (29.27) 44 (35.77) 43 (34.96) 
SU_.2.2_0rt 
Distancing 39 (31.97) 35 (28.69) 48 (39.34) 
Behavioral Escape 32 (26.45) 41 (33.88) 48 (39.67) 
Avoidance 
Cognitive Escape 32 (26.45) 41 (33.88) 48 (39.67) 
Avoidance 
Focusin__g_ on Positive 37 (29.84) 35 (28.23) 52 (41.94) 
Patients Prescribed Protease-inhibitor Medications: 
Seeking Social 23 (30.67) 20 (26.67) 32 (42.67) 
Su_QQ_ort 
Distancin__g_ 22 (29.33) 20 (44.00) 31 (26.67) 
Behavioral Escape 23 (31.08) 25 (33.78) 26 (35.14) 
Avoidance 
Cognitive Escape 18 (25.35) 24 (33.80) 29 (40.85) 
Avoidance 
Focusin__g_ on Positive 16 (21.62) 25 (33.78) 33 (44.59) 
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Table 5: Adherence status by frequency of use of coping style in patients on 
Antiretroviral medications: 
Adheren 100% adherence 95% adherence MAS adherence 
ce Adh. Non-adh. Adh. Non-adh. Adh. Non-adh. 
CoQini:; N(%) N(%) N(%) N(%) N(%) N(%) 
SSS very 21 (48.8) 22 (51.2) 37 (86.1) 6 (13.9) 20(44.4) 25(55.5 
often 6) 
SSS 22 (50.0) 22 (50.0) 38 (86.3) 6 (13.7) 23(50.0) 23(50.0 
often 0) 
SSS 16 (44.4) 20 (55.6) 32 (88.8) 4(11.1) 14(38.8) 22(61.1 
seldom 1) 
dis very 26 (54.1) 22 (45.8) 43 (89.5) 5 (10.5) 24(48.9) 25(51.0 
often 2) 
dis 16 (45.7) 19 (54.3) 29 (82.8) 6 (17.2) 16( 42.l) 22(57.8 
often 9) 
dis 18(46.2) 21 (53.8) 35 (89.7) 4 (10.3) 18( 46.l) 21(53.8 
seldom 5) 
fop 25 (48.0) 27 (51.9) 49 (94.2) 3 (5.7) 26(47.2) 29 
very (52.7) 
often 
fop 18(51.4) 17 (48.5) 28 (80.0) 7 (20) 16 (45.7) 19 
often (54.2) 
fop 16 (43.2) 21 (56.7) 31 (83.7) 6 (16.3) 15 (40.5) 22 
seldom (59.4) 
bea 23 (47.9) 25 (52.1) 40 (83.3) 8 (16.6) 20 (40.0) 30 
very (60.0) 
often 
bea 15 (36.5) 26 (63.4) 35 (85.3) 6 (14.7) 15 (34.8) 28(65.1) 
often 
bea 21 (65.6) 11 (34.4) 31 (96.8) 1 (3.2) 21(65.6) 11(34.3 
seldom 8) 
cea 25 (52.0) 23 (47.9) 42 (87.5) 6 (12.5) 23 (47.9) 25 
very (52.1) 
often 
cea 17 (41.4) 24 (58.6) 33 (80.4) 8 (19.5) 17 (38.6) 27(61.4) 
often 
cea 16 (50.0) 16 (50.0) 30 (93.7) 2 (6.3) 17 (51.5) 16 
seldom (48.8) 
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Table 6: Adherence status by frequency of use of coping style in patients on 
Protease inhibitor medications: 
Adherence 100% adherence MAS adherence 
Adh. Non-adh. Adh. Non-adh. Co[!in1:; 
N(%) N(%) N(%) N(%) 
SSS very 16 (50.0) 16 (50.0) 16 (50.00) 
often 16 (50.00) 
sss often 13 (56.5) 10 (43.51 8 (40.001 12 (60.00) 
SSS 7 (38.8) 11 (61.9) 12 (52.17) 11 (47.83) 
seldom 
dis very 14 (45.1) 17 (54.9) 17 (51.52) 16 (48.48) 
often 
dis often 12 (57.1) 9 (42.9) 7 (35.00) 13 (65.00) 
dis 10 (47.6) 11 (52.4) 12 (54.55) 10 (45.45) 
seldom 
fop very 15 (48.3) 16 (61.7) 17 (51.52) 16 (48.48) 
often 
fo..2._ often 11 (44.0) 14 (56.0l 11 (44.00) 14 (56.00) 
fop 10 (58.8) 7 (41.1) 8 (50.00) 8 (50.00) 
seldom 
bea very 16 (51.6) 15 (48.3) 12 (46.15) 14 (53.85) 
often 
bea often 9 (37.5) 15 (62.5) 10 (40.00) 15 (60.00) 
bea 11 (61.1) 7 (38.9) 13 (56.52) 10 (43.48) 
seldom 
cea very 15 (57.6) 11 (42.3) 15 (51.72) 14 (48.28) 
often 
cea often 11 (44.0) 14 (56.0) 12 (50.00) 12 (50.00) 
cea 10 (55.5) 8 (44.4) 9 (50.00) 9 (50.00) 
seldom 
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Table 7: Multiple Chi-Square Tests with Adherence to Antiretroviral 
Medications with 100% cut off (Categorical Dependent Variable) and other 
Categorical Independent Variables. 
Categorical I.V. Adherent Non-Adherent p-value 
N_(o/tl_ O/o 
Age 
< 35 yrs. 42.55 (20) 57.45 (27) NS 
35-41 yrs. 51.11 (23) 48.89 (22) 
2: 42 J'!'_S. 50.00 (20) 50.00 (20) 
Yrs. of education 
<12 yrs. 53.49 (23) 46.51 (20) NS 
:::::: 12 yrs. 51.14 (45) 48.86_(43) 
Gender 
Male 46.32 (44) 53.68 (51) NS 
Female 52.78 (19) 42.22 (17) 
Insurance 
None 38.10 (8) 61.90 (13) NS 
Some 49.07 (53) 50.93 (55) 
Current Health 
Status 
Good-Excellent 48.45 (47) 51.55 (50) NS 
Poor-Fair 45.71 (16) 54.29 _(19) 
Ethnicity 
Whites 50.00 (42) 50.00 (42) NS 
Non-Whites 44.68 (21) 55.32 (26) 
Living 
Arrangement 
Alone 44.74 (17) 55.26 (21) NS 
With Others 48.94 (46) 51.06 (48) 
Annual Family 
Income 
<15,000 50.00 (38) 50.00 (38) NS 
>15,000 46.94_(23) 53.06 (26) 
Bodily Pain 
None-Mild 48.15 (26) 51.85 (28) NS 
Moderate-Sever 47.44 (37) 52.56 (41) 
Time Since 
Diagnosis 
<1 month-2 years 46.43 (39) 53.57 (45) NS 
3-4 years 45.83 (11) 54.17 (13) 
> 5 years 50.00 (11) 50.00 (11) 
T-Cell Count 
:s 200 45.45 (30) 54.55 (36) NS 
>200 46.67 (28) 53.33 (32) 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
62 
Table 8: Multiple Chi-Square Tests with Adherence to Antiretroviral 
Medications with 95% Cut off (Categorical Dependent Variable) and other 
Categorical Independent Variables. 
Categorical I.V. Adherent Non-Adherent p-value 
O/o % 
Age 
< 35 yrs. 91.94 (43) 8.51 (4) NS 
35-41 yrs. 86.67 (39) 13.33 (6) 
~42~s. 77.50 (31) 22.50 (9) 
Yrs. of education 
<12 yrs. 79.07 (34) 20.93 (9) NS 
> 12~s. 88.64 (78) 11.36 (10) 
Gender 
Male 86.32 (82) 13.68 (13) NS 
Female 83.33 (30) 16.67 (6) 
Insurance 
None 95 .24 (20) 4.76 (1) -
Some 84.26 (91) 15.74 (17) 
Current Health 
Status 
Good-Excellent 82.47 (80) 5.71 (2) NS 
Poor-Fair 94.29 (33) 17.53 (17) 
Ethnicity 
Whites 83.33 (70) 16.67 (14) NS 
Non-Whites 89.36 (42) 10.64 (5) 
Living 
Arrangement NS 
Alone 78.95 (30) 21.05 (8) 
With Others 88.30 (83) 11.70 (11) 
Annual Family 
Income 
<15,000 86.84 (66) 13.16 (10) NS 
>15,000 83.67 (41) 16.33 (8) 
Bodily Pain 
None-Mild 83.33 (65) 16.67 (13) NS 
Moderate-Sever 88.89 (48) 11.111_6) 
Time Since 
Diagnosis 
<1 month-2 years 92.86 (78) 7.14 (6) -
3-4 years 66.67 (16) 33.33 (8) 
> 5 _years 77.27 (17) 22.73 (5) 
T-Cell Count 
::::200 83.33 (55) 16.67 (11) NS 
>200 86.67 (52) 13.33 (8) 
Note: If a :s._0.05 then p- value is significant, NS= Non Significant 
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Table 9: Multiple Chi-Square Tests with Adherence to Antiretroviral 
Medications using MAS (Categorical Dependent Variable) and other 
C t . I I d d t V ' bl a e_g_onca n e_E._en en ana es. 
Categorical I.V. Adherent Non-Adherent p-value 
% % 
Age 
< 35 yrs. 37.50 (18) 62.50 (30) NS 
35-41 yrs. 51.06 (24) 48.94 (23) 
~42~. 47.62 (20) 53.38 (22) 
Yrs. of education 
<12 yrs. 47.83 (22) 52.17 (24) NS 
> 12 _TI_S. 44.44 (40) 55.56 (50) 
Gender 
Male 43.88 (43) 56.12 (55) NS 
Female 47.37 (18) 52.63(20) 
Insurance 
None 45.45 (10) 54.55 (12) NS 
Some 44.46 (50) 55.36 (62) 
Current Health 
Status 
Good-Excellent 46.00 (46) 54.00 (54) NS 
Poor-Fair 43.24 (16) 56.76 (21) 
Ethnicity 
Whites 48.28 (42) 51.72 (45) NS 
Non-Whites 40.82 (20) 59.18 (29) 
Living 
Arrangement 
Alone 40.00 (16) 60.00 (24) NS 
With Others 47.42 (46) 52.58 (51) 
Annual Family 
Income 
<15,000 44.30 (35) 55.70 (44) NS 
>15,000 46.00 (23) 54.00 (27) 
Bodily Pain 
None-Mild 45 .12 (37) 54.88 (45) NS 
Moderate-Sever 45.45 (25) 54.55 (30) 
Time Since 
Diagnosis 
<l month-2 years 44.19 (38) 55.81 (48) NS 
3-4 years 44.00 (11) 56.00 (14) 
> 5 _x_ears 47.83 (11) 52.17(12) 
T-Cell Count 
_'.S200 39.13 (27) 60.87 (42) NS 
>200 50.82 (31) 49.18 (30) 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
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Table 10: Multiple Chi-Square Tests with Adherence to Protease inhibitor 
Medications with 100% cut off (categorical Dependent Variable) and other 
C t . 1 I d d V . bl a e_g_onca n e_p_en ent ana es. 
Categorical I.V. Adherent Non-Adherent p-value 
O/o O/o 
Age 
< 35 yrs. 53.33 (16) 46.67 (14) NS 
35-41 yrs. 48.15 (13) 51.85 (14) 
~ 4 2 J-'!'_S. 44.44 (8) 55.56 (10) 
Yrs. of education 
<12 yrs. 50.00 (8) 50.00 (8) NS 
> 12 J-'!'_S. 50.00 (29) 50.00 (29) 
Gender 
Male 57.14 (32) 42.86 (24) 0.02* 
Female 26.32 (5) 73 .68 (14) 
Insurance 
None 33.33 (3) 66.67 (6) NS 
Some 51.52 (34) 48.48 (32) 
Current Health 
Status 
Good-Excellent 50.00 (30) 50.00 (30) NS 
Poor-Fair 46.67 (7) 53 .33 (8) 
Ethnicity 
Whites 50.88 (29) 49.12 (28) NS 
Non-Whites 41.18 (7) 58.82 (10) 
Living 
Arrangement NS 
Alone 50.00 (10) 50.00 (10) 
With Others 49.09 (27) 50.91 (28) 
Annual Family 
Income 
<15,000 45.24 (19) 54.76 (23) NS 
>15,000 53.13(17) 46.88 (15) 
Bodily Pain 
None-Mild 52.38 (22) 47.62 (20) NS 
Moderate-Sever 45.45 (15) 54.55 (18) 
Time Since 
Diagnosis 
<l month-2 years 47.92 (23) 52.08 (25) NS 
3-4 years 50.00 (7) 50.00 (7) 
~ 5 _y_ears 53.85 (7) 46.15(6) 
T-Cell Count 
:::: 200 40.63 (13) 59.38 (19) NS 
>200 52.50 (21) 47.50 (19) 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table 11: Multiple Chi-Square Tests with Adherence to Protease Inhibitor 
Medications using MAS (categorical Dependent Variable) and other 
C t . 1 I d d V . bl a e_g_onca n e_..E_en ent ana es. 
Categorical I.V. Adherent Non-Adherent p-value 
% O/o 
Age 
< 35 yrs. 50.00 (14) 50.00 (14) NS 
35-41 yrs. 44.44 (12) 55.56 (15) 
2: 4 2 J'.!:_S . 50.00 (11) 50.00 (11) 
Yrs. of education 
<12 yrs. 43.71 (7) 56.25 (9) NS 
2: 12 yrs. 50.00 (30) 50.00 (30) 
Gender 
Male 50.88 (29) 49.12 (28) NS 
Female 36.84 (7) 63 .16 (12) 
Insurance 
None 50.00 (5) 50.00 (5) -
Some 47.76 (32) 52.24 (35) 
Current Health 
Status 
Good-Excellent 50.00 (31) 50.00 (31) NS 
Poor-Fair 40.00 (6) 60.00 (9) 
Ethnicity 
Whites 51.72 (30) 48.28 (28) NS 
Non-Whites 38.89 (7) 61.11 (11) 
Living 
Arrangement NS 
Alone 45.45 (10) 54.55 (12) 
With Others 49.09 (27) 50.91 (28) 
Annual Famil:y 
Income 0.90 
<15,000 39.53 (17) 60.47 (26) fisher=O .16 
2:15,000 56.25 (18) 43.75 (14) * 
Bodil:y Pain 
None-Mild 51.11 (23) 48.89 (22) NS 
Moderate-Sever 43.75 (14) 56.25 (18) 
Time Since 
Diagnosis 
<1 month-2 years 45.65 (21) 54.35 (25) NS 
3-4 years 50.00 (8) 50.00 (8) 
2: 5 _years 53.33 (8) 46.67 (7) 
T-Cell Count 
:s 200 33.33 (12) 66.67 (24) 0.03* 
>200 57.89 (22) 42.11 (16) 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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( Table. 12: Multiple T tests with "Seeking social support" (Continuous primary I.V.) and other Independent Variables (Categorical) for people 
prescribed anti-retroviral medication: 
Inde_p_endent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 34.61 NS 
:::: 12_ES. 33.09 
Gender 
Male 33.6 NS 
Female 33.7 
Insurance 
None 27.5 0.0003* 
Some 34.7 
Current Health Status 
Good-Excellent 34.0 NS 
Poor-Fair 32.2 
Ethnicity 
Whites 33.6 NS 
Non-Whites 33.5 
Living Arrangement 
Alone 36.9 0.005* 
With Others 32.2 
Annual Family Income 
<15,000 32.9 NS 
>15,000 34.2 
Bodily Pain 
None-Mild 32.5 NS 
Moderate-Sever 35.3 
Years of Education 
<12 years 34.4 NS 
>12 years 33.2 
T-Cell Count 
:s 200 32.7 NS 
>200 34.4 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 13: Multiple T tests with "Distancing" (Continuous primary I.V.) and 
other Independent Variables (Categorical) for people prescribed anti-
retroviral medication: 
Indep_endent Variables Means _1!_-value 
Yrs. of education 
<12 yrs. 34.71 NS 
2: 12 yrs. 35.84 
Gender 
Male 36.7 NS 
Female 33.2 
Insurance 
None 36.5 NS 
Some 34.9 
Current Health Status 
Good-Excellent 36.1 NS 
Poor-Fair 33.6 
Ethnicity 
Whites 33.8 NS 
Non-Whites 36.7 
Living Arrangement 
Alone 38.7 0.03* 
With Others 33.9 
Annual Family Income 
<15,000 35.2 NS 
>15,000 36.6 
Bodily Pain 
None-Mild 34.1 NS 
Moderate-Sever 36.4 
Years of Education 
<12 years 35.3 NS 
>12 _years 35.1 
T-Cell Count 
~200 34.0 NS 
>200 36.1 
Note: If a ~0.05 then p- value is significant, NS= Non Significant 
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Table. 14: Multiple T tests with "Focusing on Positive" (continuous primary 
I.V.) and other Independent Variables (Categorical) for people prescribed 
an ti-retroviral medication: 
lnde_Qendent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 26.61 NS 
> 12 yrs. 25.09 
Gender 
Male 25.9 NS 
Female 24.6 
Insurance 
None 21.8 0.007* 
Some 26.2 
Current Health Status 
Good-Excellent 26.3 0.03* 
Poor-Fair 23.5 
Ethnicity 
Whites 25.0 NS 
Non-Whites 26.7 
Living Arrangement 
Alone 27.4 0.05* 
With Others 24.8 
Annual Family Income 
<15,000 24.4 0.02* 
>15,000 27.2 
Bodily Pain 
None-Mild 25.8 NS 
Moderate-Sever 25.1 
Years of Education 
<12 years 25.2 NS 
>12 years 26.4 
T-Cell Count 
::::200 24.9 NS 
>200 26.2 
Note: If a :::_0.05 then p- value is significant, NS= Non Significant 
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( Table. 15: Multiple T tests with "Behavioral Escape Avoidance" 
(Continuous primary I.V.) and other Independent Variables (Categorical) 
for people prescribed anti-retroviral medication: 
Inde_p_endent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 22.87 NS 
2: 12 ES· 21.95 
Gender 
Male 22.4 NS 
Female 21.7 
Insurance 
None 22.3 NS 
Some 22.2 
Current Health Status 
Good-Excellent 21.8 NS 
Poor-Fair 23.2 
Ethnicity 
Whites 21.5 NS 
Non-Whites 23.6 
Living Arrangement 
Alone 24.1 0.03* 
With Others 21.5 
Annual Family Income 
<15,000 22.6 NS 
2:15,000 21.7 
Bodily Pain 
None-Mild 21.2 0.01 * 
Moderate-Sever 23.9 
Years of Education 
<12 years 22.9 NS 
>12 years 21.9 
T-Cell Count 
:s 200 22.0 NS 
>200 22.3 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 16: Multiple T tests with "Cognitive Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed anti-retroviral medication: 
Independent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 29.2 NS 
> 12 yrs. 27.81 
Gender 
Male 27.9 NS 
Female 28.8 
Insurance 
None 28.0 NS 
Some 28.2 
Current Health Status 
Good-Excellent 28.2 NS 
Poor-Fair 28.2 
Ethnicity 
Whites 27.2 0.01 * 
Non-Whites 30.2 
Living Arrangement 
Alone 29.0 NS 
With Others 27.9 
Annual Family Income 
<15,000 27.8 NS 
>15,000 28.7 
Bodily Pain 
None-Mild 28.8 NS 
Moderate-Sever 27.3 
Years of Education 
<12 years 27.6 NS 
>12 years 29.6 
T-Cell Count 
:::;200 28.3 NS 
>200 27.8 
Note: If a< 0.05 then p- value is significant, NS= Non Significant 
71 
Table. 17: ANOVA between the categorical I.V's "Time Since Diagnosis", 
"age" and continuous primary Independent Variables for people prescribed 
An ti-retroviral medication: 
Dependent R-square F-value p-value 
Variable 
Time Since Dia_g_nosis 
Seeking social 0.00 0.03 NS 
SUJ!.l!_Ort 
Distancin_g_ 0.00 0.09 NS 
Focusing on 0.00 0.2 NS 
_p_ositive 
Behavioral escape 0.02 1.7 NS 
avoidance 
Cognitive escape 0.04 2.5 NS 
avoidance 
A_g_e 
Seeking social 0.01 0.63 NS 
SUJ!.l!_Ort 
Distancin_g_ 0.03 1.96 NS 
Focusing on 0.03 2.19 NS 
_Qositive 
Behavioral escape 0.01 0.94 NS 
avoidance 
Cognitive escape 0.00 0.05 NS 
avoidance 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 18: Multiple T tests with "Seeking social support" (Continuous 
primary l.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medication: 
lnd~endent Variables Means 1!_-value 
Yrs. of education 
<12 yrs. 32.75 NS 
> 12 yrs. 33.31 
Gender 
Male 33.4 NS 
Female 32.4 
Insurance 
None 25.3 0.002* 
Some 34.2 
Current Health Status 
Good-Excellent 33.9 NS 
Poor-Fair 30.4 
Ethnicity 
Whites 33.9 NS 
Non-Whites 30.6 
Living Arrangement 
Alone 35.8 NS 
With Others 32.2 
Annual Family Income 
<15,000 33.3 NS 
>15,000 32.4 
Bodily Pain 
None-Mild 31.4 0.03* 
Moderate-Sever 35.5 
Years of Education 
<12 years 32.7 NS 
>12 _years 33.3 
T-Cell Count 
:s 200 32.8 NS 
>200 33.4 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 19: Multiple T tests with "Distancing" (Continuous primary I.V.) and 
other Independent Variables (Categorical) for people prescribed Protease-
inhibitor medication: 
Independent Variables Means _1!_-value 
Yrs. of education 
<12 yrs. 34.58 NS 
> 12_2'.!:_S. 36.15 
Gender 
Male 36.1 NS 
Female 31.3 
Insurance 
None 33.9 NS 
Some 39.0 
Current Health Status 
Good-Excellent 35.8 NS 
Poor-Fair 30.6 
Ethnicity 
Whites 33.7 NS 
Non-Whites 36.2 
Living Arrangement 
Alone 36.9 NS 
With Others 33.3 
Annual Family Income 
<15,000 33.6 NS 
>15,000 36.4 
Bodily Pain 
None-Mild 31.7 NS 
Moderate-Sever 36.4 
Years of Education 
<12 years 34.5 NS 
>12 years 34.5 
T-Cell Count 
<200 34.3 NS 
>200 34.7 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
74 
\ 
Table. 20: Multiple T tests with "Focusing on Positive" (continuous primary 
I.V.) and other Independent Variables (Categorical) for people prescribed 
Protease-inhibitor medication: 
lnde~endent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 25.93 NS 
> 121'.!:_S. 25.82 
Gender 
Male 26.5 NS 
Female 23.7 
Insurance 
None 21.8 0.04* 
Some 26.4 
Current Health Status 
Good-Excellent 26.4 NS 
Poor-Fair 23.4 
Ethnicity 
Whites 25.7 NS 
Non-Whites 26.2 
Living Arrangement 
Alone 27.5 NS 
With Others 25.2 
Annual Famil:y Income 
<15,000 25.3 NS 
>15,000 26.0 
Bodil:y Pain 
None-Mild 25.5 NS 
Moderate-Sever 26.2 
Years of Education 
<12 years 25.9 NS 
>12 years 25.8 
T-Cell Count 
:::200 25.5 NS 
>200 26.1 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
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( Table. 21: Multiple T tests with "Behavioral Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medication: 
lnde_.l!_endent Variables Means _p_-value 
Yrs. of education 
<12 yrs. 22.5 NS 
2: 12 _2'.!:_S. 22.10 
Gender 
Male 22.5 NS 
Female 21.1 
Insurance 
None 21.5 NS 
Some 22.2 
Current Health Status 
Good-Excellent 22.0 NS 
Poor-Fair 22.8 
Ethnicity 
Whites 21.8 NS 
Non-Whites 23.1 
Living Arrangement 
Alone 25.0 0.008* 
With Others 21.1 
Annual Family Income 
<15,000 23.1 NS 
2:15,000 20.9 
Bodily Pain 
None-Mild 21.3 NS 
Moderate-Sever 23.3 
Years of Education 
<12 years 22.1 NS 
>12 _1'._ears 22.5 
T-Cell Count 
::::200 22.2 NS 
>200 21.9 
Note: If a .:s_0.05 then p- value is significant, NS= Non Significant 
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Table. 22: Multiple T tests with "Cognitive Escape Avoidance" (Continuous 
primary I.V.) and other Independent Variables (Categorical) for people 
prescribed Protease-inhibitor medication: 
lnde_p_endent Variables Means _Q-value 
Yrs. of education 
<12 yrs. 29.23 NS 
~ 12_.l'.!:_S. 27.30 
Gender 
Male 27.8 NS 
Female 27.1 
Insurance 
None 27.0 NS 
Some 27.7 
Current Health Status 
Good-Excellent 27.9 NS 
Poor-Fair 26.3 
Ethnicity 
Whites 27.2 NS 
Non-Whites 29.5 
Living Arrangement 
Alone 29.0 NS 
With Others 27.1 
Annual Family Income 
<15,000 27.2 NS 
~15,000 27.8 
Bodily Pain 
None-Mild 28.2 NS 
Moderate-Sever 26.7 
Years of Education 
<12 years 27.3 NS 
~12 years 29.2 
T-Cell Count 
:::: 200 28.5 NS 
>200 26.4 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 23: ANOVA between the categorical I.V's "Time Since Diagnosis", 
"age" and continuous primary Independent Variables for people prescribed 
Protease-inhibitor medication: 
Dependent R-square F-value p-value 
Variable 
Time Since Di~nosis 
Seeking social 0.00 0.03 NS 
SU Hort 
Distancin_g_ 0.00 0.1 NS 
Focusing on 0.01 0.5 NS 
_p_ositive 
Behavioral escape 0.05 2.0 NS 
avoidance 
Cognitive escape 0.1 3.7 0.02* 
avoidance 
A_g_e 
Seeking social 0.01 0.68 NS 
suHort 
Distancin_g_ 0.06 2.36 NS 
Focusing on 0.04 1.72 NS 
_p_ositive 
Behavioral escape 0.02 0.79 NS 
avoidance 
Cognitive escape 0.00 0.09 NS 
avoidance 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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( Table. 24: Logistic Regression Analysis between Percentage Adherence to Anti-retroviral Medication With 100% cut off and 'Seeking Social Support'. 
Independent Odds ratio Parameter Wald's 
Variables Point 95% Wald's estimate p-value 
estimate C.I. 
ssshigh 0.5 0.1-1.7 -0.5 NS 
sssmed 0.7 0.2-2.0 -0.3 NS 
highage 0.5 0.2-1.6 -0.5 NS 
med age 0.7 0.2-2.0 -0.2 NS 
Health status 0.7 0.2-2.1 -0.3 NS 
Ethnicity 0.9 0.3-2.7 -0.004 NS 
Education 1.0 0.4-2.6 -0.09 NS 
Employment 0.6 0.2-1.6 -0.5 NS 
Insurance 0.6 0.1-2.0 -0.4 NS 
Income 1.0 0.4-2.4 0.02 NS 
Bodily pain 1.9 0.7-5.0 0.6 NS 
Longtime 1.3 0.4-4.1 0.2 NS 
Medtime 1.6 0.4-6.4 0.5 NS 
CD4 count 1.3 0.5-3.3 0.3 NS 
Note: If a :::_0.05 then p- value is significant, NS= Non Significant 
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Table. 25: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication With 100% cut off and 'Distancing'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
dishigh 0.9 0.3-2.4 -0.09 NS 
dismed 0.7 0.2-1.9 -0.3 NS 
Health 0.8 0.2-2.4 -0.2 NS 
status 
Education 1.0 0.4-3.5 0.08 NS 
Living 0.9 0.3-2.3 -0.08 NS 
arrangement 
Insurance 0.5 0.1-1.8 -0.5 NS 
Income 1.0 0.4-2.5 0.09 NS 
Bodily pain 1.3 0.5-3.2 0.2 NS 
CD4 count 1.0 0.4-2.3 0.08 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 26: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication With 100% cut off and 'Focusing on Positive'. 
Independent Odds ratio Parameter Wald's 
Variables Point estimate 95% Wald's estimate p-value 
C.I. 
fop high 0.9 0.3-2.5 -0.03 NS 
fopmed 1.2 0.4-3.5 0.2 NS 
Health status 0.8 0.3-2.2 -0.1 NS 
Education 1.1 0.5-2.6 0.1 NS 
Employment 0.7 0.3-1.7 -0.3 NS 
Insurance 0.5 0.1-1.7 -0.5 NS 
Income 1.2 0.5-2.7 0.1 NS 
Bodily pain 1.1 0.5-2.8 0.1 NS 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
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Table. 27: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication With 100% cut off and 'Escape Avoidance 
Coping'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
beahigh 0.3 0.1-0.9 -1.1 0.04* 
beamed 0.1 0.05-0.6 -1.6 0.005* 
Education 1.0 0.4-2.6 0.08 NS 
Living 1.0 0.4-2.5 0.02 NS 
arrangement 
Insurance 0.4 0.1-1.3 -0.8 NS 
Income 1.1 0.5-2.7 0.1 NS 
Bodily pain 1.6 0.6-3.8 0.4 NS 
CD4 count 0.8 0.3-1.9 -0. l NS 
With 'Cognitive Escape Avoidance' 
ceahigh 0.9 0.3-2.4 -0.05 NS 
ceamed 0.7 0.2-1.9 -0.3 NS 
Employment 0.7 0.2-1.8 -0.3 NS 
Living 0.8 0.3-1.8 -0.2 NS 
arrangement 
Insurance 0.6 0.2-1.8 -0.4 NS 
Income 1.0 0.4-2.3 0.03 NS 
Bodily pain 1.2 0.5-2.8 0.2 NS 
CD4 count 1.0 0.4-2.4 0.08 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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( Table. 28: Logistic Regression Analysis between Percentage Adherence to Anti-retroviral Medication With 95% cut off and 'Seeking Social Support'. 
Independent Odds ratio Parameter Wald' s 
Variables Point estimate 95% Wald 's estimate p-value 
C.I. 
ssshigh 1.1 0.2-6.0 0. 1 NS 
sssmed 0.6 0.1-2.9 -0.4 NS 
Gender 0.4 0.1-1.7 -0.7 NS 
Ethnicity 0.3 0.07-1.3 -1.1 NS 
Education 0.2 0.06-0.8 -1.4 0.02* 
Employment 0.2 0.03-1.2 -1.5 NS 
Living 0.2 0.06-1.0 -1.2 NS 
arrangement 
Income 1.4 0.4-5.0 0.3 NS 
CD4 count 1.5 0.4-5 . l 0.4 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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( Table. 29 Logistic Regression Analysis between Percentage Adherence to Anti-retroviral Medication With 95% cut off and 'Distancing'. 
Independent Odds ratio Parameter Wald's 
Variables Point estimate 95% Wald's estimate p-value 
C.I. 
dishigh 1.3 0.2-7.4 0.3 NS 
dismed 0.7 0.1-3.7 -0.2 NS 
Gender 0.5 0.1-1.8 -0.6 NS 
Ethnicity 0.4 0.09-1.9 -0.8 NS 
Education 0.2 0.08-0.9 -1.2 0.02* 
Employment 0.2 0.04-1.4 -1.3 NS 
Living 0.3 0.08-1.3 -1.1 NS 
arrangement 
Income 1.3 0.4-4.6 0.3 NS 
CD4 count 1.2 0.3-4.3 0.2 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 30 Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication With 95% cut off and 'Focusing on Positive'. 
Independent Odds ratio Parameter Wald's 
Variables Point estimate 95% Wald's estimate p-value 
C.I. 
Fop high 3.7 0.7-20.0 1.3 NS 
fop med 0.4 0.1-1.9 -0.7 NS 
Gender 0.4 0.1-1.6 -0.7 NS 
Ethnicity 0.4 0.09-1.7 -0.8 NS 
Education 0.2 0.07-0.9 -1.3 0.03* 
Employment 0.5 0.09-2.7 -0.6 NS 
Living 0.1 0.04-0.7 -1.6 0.02* 
arrang_ement 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table. 31 Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication With 95% cut off and 'Escape Avoidance 
Coping'. 
In de pen den Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
beahigh 0.1 0.01-1.8 -1.6 NS 
beamed 0.2 0.02-2.2 -1.4 NS 
Gender 0.4 0.1-1.5 -0.8 NS 
Ethnicity 0.3 0.07-1.4 -1.1 NS 
Education 0.2 0.087-1.0 -1.2 NS 
Employment 0.3 0.06-1 .8 -1.0 NS 
Living 0.4 0.1-1.6 -0.8 NS 
arrangement 
CD4 count 1.4 0.4-4.8 0.3 NS 
With 'Cognitive Escape Avoidance' 
ceahigh 0.4 0.06-2.6 -0.8 NS 
ceamed 0.2 0.03-1.3 -1.4 NS 
Gender 0.4 0.1-1.6 -0.7 NS 
Ethnicity 0.2 0.06-1.1 -1.2 NS 
Education 0.2 0.06-0.7 -1.5 NS 
Employment 0.2 0.04-1.4 -1.3 NS 
Living 0.3 0.08-1.1 -1.1 NS 
arrangement 
CD4 count 1.7 0.5-6.0 0.5 NS 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
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Table. 32 Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 100% cut off and 'Seeking Social 
Support'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ceahigh 0.8 0.2-3.5 -0.1 NS 
ceamed 0.9 0.2-4.2 -0.003 NS 
Gender 0.2 0.05-0.7 -1.6 0.02* 
Education 1.2 0.3-4.9 0.3 NS 
Insurance 0.4 0.07-2.3 -0.8 NS 
Income 0.8 0.2-2.7 -0.1 NS 
Bodily pain 0.7 0.2-2.2 -0.2 NS 
CD4 count 1.4 0.4-4.2 0.3 NS 
Note: If a ::::_0.05 then p- value is significant, NS= Non Significant 
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Table. 33 Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 100% cut off and 'Distancing'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ceahigh 0.6 0.2-2.3 -0.3 NS 
ceamed 0.9 0.2-3.6 -0.05 NS 
Gender 0.2 0.07-0.8 -1.4 0.02* 
Ethnicity 1.5 0.4-5.1 0.4 NS 
Education 1.4 0.4-5.0 0.3 NS 
Bodily pain 0.7 0.2-1.9 -0.3 NS 
Note: If a :s._0.05 then p- value is significant, NS= Non Significant 
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( Table. 34 Logistic Regression Analysis between Percentage Adherence to Protease-inhibitor Medication With 100% cut off and 'Focusing on Positive' . 
Independen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ceahigh 0.2 0.06-1.2 -1.2 NS 
ceamed 0.2 0.06-1.2 -1.2 NS 
Gender 0.1 0.04-0.7 -1.7 0.01 * 
Insurance 0.2 0.05-1.4 -1.3 NS 
Income 0.5 0.1-1.9 -0.5 NS 
Bodily pain 0.9 0.3-2.7 -0.09 NS 
CD4 count 1.5 0.4-4.2 0.3 NS 
Note: If a :s._0.05 then p- value is significant, NS= Non Significant 
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Table. 35 Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 100% cut off and 'Escape Avoidance 
Coping'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
ceahigh 0.5 0.1-2.0 -0.6 NS 
ceamed 0.3 0.07-1.6 -1.0 NS 
Gender 0.1 0.04-0.6 -1.7 0.01 * 
Education 1.5 0.4-5.9 0.4 NS 
Insurance 0.3 0.06-1.9 -1.0 NS 
Bodily pain 0.8 0.2-2.4 -0.l NS 
CD4 count 1.3 0.4-3.9 0.3 NS 
With 'Cognitive Escape Avoidance' 
ceahigh 0.6 0.1-2.6 -0.4 NS 
ceamed 0.4 0.1-1.7 -0.7 NS 
Gender 0.2 0.05-0.8 -1.5 0.02* 
Education 2.0 0.5-8.2 0.7 NS 
Insurance 0.5 0.1-3.0 -0.5 NS 
Income 0.8 0.2-2.8 -0.1 NS 
Bodily pain 0.8 0.2-2.7 -0. l NS 
CD4 count 1.4 0.4-4.4 0.3 NS 
Note: If a ~0.05 then p- value is significant, NS= Non Significant 
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Table 36.: Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 95% cut off and 'Seeking Social 
Support'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ssshigh 0.5 0.07-4.8 -0.5 NS 
sssmed 0.3 0.04-3.6 -0.9 NS 
Gender 0.1 0.02-0.8 -1.8 0.03* 
Education 0.1 0.02-1.0 -1.7 NS 
Living 0.1 0.02-1.3 -1.8 NS 
arrangement 
Bodily pain 0.9 0.1-4.2 -0.1 NS 
CD4 count 1.2 0.2-6.2 0.1 NS 
Note: If a :::_0.05 then p- value is significant, NS= Non Significant 
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Table 37.: Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 95% cut off and 'Focusing on Positive'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
fop high 0.9 0.1-7.8 -0.01 NS 
fop med 0.4 0.06-3.6 -0.7 NS 
Gender 0.1 0.03-0.9 -1.7 0.03* 
Education 0.1 0.03-1.1 -1.6 NS 
Living 0.1 0.01-1.2 -1.9 NS 
arrangement 
Bodily pain 0.8 0.1-3 .8 -0.1 NS 
CD4 count 1.2 0.2-6.2 0.2 NS 
Note: If a :::_0.05 then p- value is significant, NS= Non Significant 
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Table 38.: Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 95% cut off and 'Distancing'. 
Independen Odds ratio Parameter 
t Variables Point estimate 95% Wald's estimate 
C.I. 
dishigh 3.0 0.3-25.3 1.1 NS 
dismed 0.7 0.1-4.7 -0.3 NS 
Gender 0.1 0.02-0.8 -1.9 0.03* 
Education 0.1 0.02-0.9 -1.8 0.04* 
Living 0.1 0.01-0.8 -2.2 0.03* 
arrangement 
Bodi!Y.r_ain 0.8 0.1-3.7 -0.1 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table 39.: Logistic Regression Analysis between Percentage Adherence to 
Protease-inhibitor Medication With 95% cut off and 'Escape avoidance 
coping'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
beahigh 0.3 0.02-3.6 -1.1 NS 
beamed 0.4 0.03-6.4 -0.7 NS 
Gender 0.1 0.03-0.9 -1.7 0.04* 
Education 0.2 0.03-1.1 -1.5 NS 
Living 0.2 0.03-1.6 -1.4 NS 
arrangement 
Bodi!YE_ain 1.0 0.2-5.0 0.09 NS 
With 'Cognitive Escape Avoidance' 
ceahigh 1.1 0.1-9.5 0.1 NS 
ceamed 0.8 0.1-5.7 -0.2 NS 
Gender 0.1 0.03-0.7 -1.8 0.02* 
Education 0.2 0.03-1.7 -1.3 NS 
Living 0.2 0.03-1.7 -1.4 NS 
arrangement 
Bodily pain 0.9 0.2-4.6 -0.02 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table 40.: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication using Medication adherence scale and 'Seeking 
Social Support'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ssshigh 0.6 0.2-1.8 -0.4 NS 
sssmed 0.9 0.3-2.4 -0.1 NS 
highage 0.3 0.1-1.1 -0.9 NS 
medage 0.9 0.3-2.4 -0.09 NS 
Health 0.6 0.2-1.8 -0.4 NS 
status 
Education 1.1 0.4-2.8 0.1 NS 
Insurance 0.7 0.2-2.5 -0.2 NS 
Income 0.6 0.2-1.4 -0.4 NS 
Bodily pain 2.2 0.8-5.6 0.7 NS 
Longtime 1.8 0.5-5.9 0.6 NS 
Med time 1.5 0.3-6.1 0.4 NS 
CD4count 2.1 0.9-4.9 0.7 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
95 
Table 41.: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication using Medication adherence scale and 
'Distancing'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
dishigh 0.8 0.3-2.1 -0.2 NS 
dismed 0.5 0.2-1.5 -0.5 NS 
Gender 1.0 0.4-2.6 0.04 NS 
Health 0.6 0.2-2.1 -0.3 NS 
status 
Education 1.2 0.5-3.0 0.2 NS 
Insurance 0.7 0.2-2.4 -0.2 NS 
Income 0.7 0.3-1.8 -0.2 NS 
Bodily pain 1.7 0.7-4.2 0.5 NS 
CD4count 1.8 0.8-4.00 0.6 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table 42.: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication using Medication adherence scale and ' Focusing 
on Positive'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald ' s estimate p-value 
C.I. 
fop high 0.7 0.2-2.1 -0.2 NS 
fop med 0.6 0.2-1.9 -0.4 NS 
Health 0.4 0.1-1.4 -0.7 NS 
status 
Living 0.5 0.2-1.3 -0.6 NS 
arrangement 
Insurance 0.5 0.1-1.8 -0.5 NS 
Income 0.7 0.3-1.6 -0.3 NS 
Bodily pain 2.2 0.9-5.6 0.8 NS 
CD4count 1.4 0.6-3.2 0.4 NS 
Note: If a :s_0.05 then p- value is significant, NS= Non Significant 
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Table 43.: Logistic Regression Analysis between Percentage Adherence to 
Anti-retroviral Medication using Medication adherence scale and 'Escape 
Avoidance Coping'. 
Independen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
beahigh 0.2 0.08-0.6 -1.4 0.005* 
beamed 0.1 0.06-0.5 -1.6 0.002* 
Income 0.8 0.3-1.9 -0.1 NS 
Bodily pain 1.8 0.7-4.2 0.5 NS 
Longtime 0.9 0.3-2.6 -0.06 NS 
med time 1.1 0.3-4.2 0.1 NS 
With 'Cognitive Escape Avoidance ' 
ceahigh 0.7 0.2-1.9 -0.2 NS 
ceamed 0.5 0.2-1.3 -0.6 NS 
Living 0.5 0.2-1.3 -0.5 NS 
arrangement 
Insurance 0.6 0.2-1.9 -0.4 NS 
Income 0.7 0.3-1.7 -0.2 NS 
Bodily pain 1.6 0.7-3.6 0.4 NS 
CD4 count 1.5 0.7-3.4 0.4 NS 
Note: If a .:::_0.05 then p- value is significant, NS= Non Significant 
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Table 44.: Logistic Regression Analysis between Percentage Adherence to 
Protease inhibitor Medication using Medication adherence scale and 
'Seeking Social Support'. 
Independen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
ssshigh 0.7 0.2-2.6 -0.2 NS 
sssmed 0.3 0.09-1.5 -0.9 NS 
Health 0.4 0.1-1.8 -0.7 NS 
status 
Bodily pain 0.9 0.3-2.9 -0.04 NS 
CD4count 3.1 1.1-8.5 1.1 NS 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
99 
( Table 45.: Logistic Regression Analysis between Percentage Adherence to Protease inhibitor Medication using Medication adherence scale and 
' Distancing'. 
Independen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald' s estimate p-value 
C.I. 
dishigh 0.8 0.2-2.7 -0.2 NS 
dismed 0.4 0.1-1.8 -0.8 NS 
Ethnicity 1.7 0.4-6.3 0.5 NS 
Education 0.5 0.1-2.2 -0.5 NS 
Income 0.3 0.1 -1.0 -1.0 NS 
Bodily pain 1.1 0.3-3.3 0.1 NS 
CD4count 3.5 1.1-10.5 1.2 NS 
Note: If a :::_0.05 then p- value is significant, NS= Non Significant 
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Table 46.: Logistic Regression Analysis between Percentage Adherence to 
Protease inhibitor Medication using Medication adherence scale and 
'Focusing on Positive'. 
lndependen Odds ratio Parameter Wald's 
t Variables Point estimate 95% Wald's estimate p-value 
C.I. 
fop high 0.7 0.1-2.7 -0.3 NS 
fop med 0.4 0.09-1.8 -0.8 NS 
Insurance 0.7 0.1-3.8 -0.2 NS 
Income 0.2 0.09-0.9 -1.2 0.03* 
Bodily pain 1.1 0.3-3.4 0.1 NS 
CD4count 3.0 1.0-8.6 1.1 NS 
Note: If a :s._0.05 then p- value is significant, NS= Non Significant 
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Table 47.: Logistic Regression Analysis between Percentage Adherence to 
Protease inhibitor Medication using Medication adherence scale and 
'Escape Avoidance Coping'. 
Independent Odds ratio Parameter Wald's 
Variables Point estimate 95% Wald's estimate p-value 
C.I. 
With 'Behavioral Escape Avoidance' 
beahigh 0.6 0.1-2.3 -0.4 NS 
beamed 0.7 0.1-3.0 -0.2 NS 
Health status 0.3 0.08-1.8 -0.9 NS 
Education 0.7 0.1-2.9 -0.3 NS 
Employment 1.6 0.4-5 .8 0.4 NS 
Income 0.3 0.1-1.1 -1.0 NS 
Bodily pain 1.1 0.3-3.6 0.1 NS 
CD4count 2.8 0.9-8.5 1.0 NS 
With 'Cognitive Escape Avoidance' 
ceahigh 0.6 0.1-2.4 -0.4 NS 
ceamed 0.8 0.2-3.0 -0.2 NS 
Insurance 0.9 0.1-4.4 -0.09 NS 
Income 0.4 0.1-1.2 -0.8 NS 
Bodily pain 1.0 0.3-3.l 0.07 NS 
CD4count 3.1 1.0-9.1 1.1 NS 
Note: If a s_0.05 then p- value is significant, NS= Non Significant 
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( 
APPENDIX II- SAS codes for adherence measures and coping. 
/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON ANTIRETROVlRAL DRUGS AS 
BEING ADHERENT OR NON ADHERENT BASED ON % CUT OFF DEFINITIONS, 
BOTH 100% AND 95 % CUT OFF'S.*/ 
options nocenter linesize=72; 
libname saurabh 'c:\Windows\Desktop\saw-abh'; 
data saurabh3; 
set saurabh.hivsurv; 
if qiilx= 'bactrirn' then qii lx2a=O; 
if qiilx= 'acyclovir' then qiilx2a=O; 
ifqiilx= 'pentamidine' then qiilx2a=O; 
if qiilx= 'zoloft' then qiilx2a=O; 
ifqiilx= 'crixivan' then qiilx2a=O; 
ifqiilx= 'ritonavir' then qiilx2a=O; 
if qiilx= 'saquinavir' then qiilx2a=O; 
if qii 1 x2a=O then qiilx13=.; 
ifqiilx13=99 then qiilx2a=.; 
if qiilx2a=l then qiilx2a=8; 
if qiilx2a=2 then qiilx2a=l2; 
ifqiilx2a=3 then qiilx2a=l5; 
if qiilx2a=4 then qiilx2a=30; 
if qiilx2a=5 then qiilx2a=60; 
ifqiilx2a=6 then qiilx2a=90; 
ifqiilx2a=7 then qiilx2a=l60; 
if qiilx2a=8 then qiilx2a=200; 
medl = qiilx13/qiilx2a; 
compl=l-medl; 
percompl =compl *100; 
if qii2x= 'bactrim' then qii2x2a=O; 
if qii2x= 'dapsone' then qii2x2a=O; 
if qii2x= 'leucovorin' then qii2x2a=O; 
if qii2x= 'ms contin' then qii2x2a=O; 
if qii2x= 'theodur' then qii2x2a=O; 
if qii2x= 'crixivan' then qii2x2a=O; 
if qii2x= 'saquinavi.r' then qii2x2a=O; 
if qii2x= 'indinavir' then qii2x2a=O; 
if qii2x= 'ritonavir' then qii2x2a=O; 
if qii2x2a=O then qii2x13=.; 
if qii2x13=99 then qii2x2a=.; 
if qii2x2a=l then qii2x2a=8; 
if qii2x2a=2 then qii2x2a=l 2; 
if qii2x2a=3 then qii2x2a=l 5; 
if qii2x2a=4 then qii2x2a=30; 
if qii2x2a=5 then qii2x2a=60; 
if qii2x2a=6 then qii2x2a=90; 
if qii2x2a=7 then qii2x2a=160; 
if qii2x2a=8 then qii2x2a=200; 
med2= qii2x13/qii2x2a; 
comp2=1-med2; 
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/ 
percomp2=comp2*100; 
if qii3x= 'acyclovir' then qii3x2a=O; 
if qii3x= 'bactrim' then qii3x2a=O; 
if qii3x= 'biaxin' then qii3x2a=O; 
if qii3x= 'clotrimazole' then qii3x2a=O; 
if qii3x= 'compazine' then qii3x2a=O; 
if qii3x= 'dapsone' then qii3x2a=O; 
if qii3x= 'diltiazem' then qii3x2a=O; 
if qii3x= 'fluconazole' then qii3x2a=O; 
if qii3x= 'mellaril' then qii3x2a=O; 
if qii3x= 'minocycline' then qii3x2a=O; 
if qii3x= 'motrin' then qii3x2a=O; 
if qii3x= 'oxandrin' then qii3x2a=O; 
if qii3x= 'vasotec' then qii3x2a=O; 
if qii3x= 'zantac' then qii3x2a=O; 
if qii3x= 'zovirax' then qii3x2a=O; 
if qii3x= 'crixivan' then qii3x2a=O; 
if qii3x= 'indinavir' then qii3x2a=O; 
if qii3x= 'invirase' then qii3x2a=O; 
if qii3x= 'norvir' then qii3x2a=O; 
if qii3x= 'ritonavir' then qii3x2a=O; 
if qii3x= 'saquinavir' then qii3x2a=O; 
if qii3x2a=O then qii3xl3=.; 
if qii3x13=99 then qii3x2a=.; 
if qii3x2a=l then qii3x2a=8; 
if qii3x2a=2 then qii3x2a=12; 
if qii3x2a=3 then qii3x2a=15; 
if qii3x2a=4 then qii3x2a=30; 
if qii3x2a=5 then qii3x2a=60; 
if qii3x2a=6 then qii3x2a=90; 
if qii3x2a=7 then qii3x2a=l 60; 
if qii3x2a=8 then qii3x2a=200; 
med3= qii3x13/qii3x2a; 
comp3=1-med3; 
percomp3=comp3*100; 
ifpercompl=. then percompl=O; 
ifpercomp2=. then percomp2=0; 
ifpercomp3=. then percomp3=0; 
totcomp= percomp 1 +percomp2+percomp3; 
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2; 
ifpercompl NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3; 
ifpercompl NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp; 
ifpercompl=O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp; 
if percomp 1 =O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp; 
iftotcomp=O then delete; 
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iftotcomp =100 then totcomp=l; 
else iftotcomp LT 100 then totcomp=O; 
if qvi 1 =O then qvi 1 =99; 
if qvi2=0 then qvi2=99; 
if qvi3=0 then qvi3=99; 
if qvi4=0 then qvi4=99; 
if qvi5=0 then qvi5=99; 
if qvi6=0 then qvi6=99; 
if qvi7=0 then qvi7=99; 
if qvi8=0 then qvi8=99; 
if qvi9=0 then qvi9=99; 
if qvilO=O then qvi 10=99; 
if qvi 11 =O then qvi 11 =99; 
if qvi 12=0 then qvi 12=99; 
if qvi 13=0 then qvi 13=99; 
if qvi14=0 then qvi14=99; 
if qvi 15=0 then qvi 15=99; 
if qvi 16=0 then qvi 16=99; 
if qvi 17=0 then qvi 17=99; 
if qvi 18=0 then qvi 18=99; 
if qvi 19=0 then qvi 19=99; 
if qvi20=0 then qvi20=99; 
if qvi21 =O then qvi21 =99; 
if qvi22=0 then qvi22=99; 
if qvi23=0 then qvi23=99; 
if qvi24=0 then qvi24=99; 
if qvi25=0 then qvi25=99; 
if qvi26=0 then qvi26=99; 
if qvi27=0 then qvi27=99; 
if qvi28=0 then qvi28=99; 
if qvi29=0 then qvi29=99; 
if qvi30=0 then qvi30=99; 
if qvi31 =O then qvi31 =99; 
if qvi32=0 then qvi32=99; 
if qvi33=0 then qvi33=99; 
if qvi34=0 then qvi34=99; 
if qvi35=0 then qvi35=99; 
if qvi36=0 then qvi36=99; 
if qvi37=0 then qvi37=99; 
if qvi38=0 then qvi38=99; 
if qvi39=0 then qvi39=99; 
if qvi40=0 then qvi40=99; 
if qvi41 =O then qvi41 =99; 
if qvi42=0 then qvi42=99; 
if qvi43=0 then qvi43=99; 
if qvi44=0 then qvi44=99; 
if qvi45=0 then qvi45=99; 
if qvi46=0 then qvi46=99; 
if qvi47=0 then qvi47=99; 
if qvi48=0 then qvi48=99; 
if qvi49=0 then qvi49=99; 
if qvi50=0 then qvi50=99; 
sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1; 
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dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvil1+qvi50+qvi37+qvi15+qvi32+qvi48+qvi52; 
fop 1=qvi26+qvi27+qvi17+qvi41 +qvi21+qvi28+qvi14+qvi4 7; 
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi 18+qvi5+qvi3+qvi25; 
cea 1 =qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l+qvi12; 
ifsssl GT 149 then sssl=O; 
if dis 1 GT 154 then disl =O; 
iffopl GT 134 then fopl=O; 
ifbeal GT 139 then beal=O; 
ifceal GT 139 then ceal=O; 
run; 
data saurabh7; 
set saurabh3; 
if qvi 1 =99 then qvi 1 =O; 
if qvi2=99 then qvi2=0; 
if qvi3=99 then qvi3=0; 
if qvi4=99 then qvi4=0; 
if qvi5=99 then qvi5=0; 
if qvi6=99 then qvi6=0; 
if qvi7=99 then qvi7=0; 
if qvi8=99 then qvi8=0; 
if qvi9=99 then qvi9=0; 
if qvi 10=99 then qvi 1 O=O; 
if qvil 1 =99 then qvil 1 =O; 
if qvi12=99 then qvi12=0; 
if qvi13=99 then qvi13=0; 
if qvi14=99 then qvi14=0; 
if qvi 15=99 then qvi 15=0; 
if qvi 16=99 then qvi 16=0; 
if qvi 17=99 then qvi 17=0; 
if qvi 18=99 then qvi 18=0; 
if qvi 19=99 then qvi 19=0; 
if qvi20=99 then qvi20=0; 
if qvi21 =99 then qvi21 =O; 
if qvi22=99 then qvi22=0; 
if qvi23=99 then qvi23=0; 
if qvi24=99 then qvi24=0; 
if qvi25=99 then qvi25=0; 
if qvi26=99 then qvi26=0; 
if qvi27=99 then qvi27=0; 
if qvi28=99 then qvi28=0; 
if qvi29=99 then qvi29=0; 
if qvi30=99 then qvi30=0; 
if qvi31 =99 then qvi31 =O; 
if qvi32=99 then qvi32=0; 
if qvi33=99 then qvi33=0; 
if qvi34=99 then qvi34=0; 
if qvi35=99 then qvi35=0; 
if qvi36=99 then qvi36=0; 
if qvi37=99 then qvi37=0; 
if qvi38=99 then qvi38=0; 
if qvi39=99 then qvi39=0; 
if qvi40=99 then qvi40=0; 
if qvi41 =99 then qvi41 =O; 
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if qvi42=99 then qvi42=0; 
if qvi43=99 then qvi43=0; 
if qvi44=99 then qvi44=0; 
if qvi45=99 then qvi45=0; 
if qvi46=99 then qvi46=0; 
if qvi47=99 then qvi47=0; 
if qvi48=99 then qvi48=0; 
if qvi49=99 then qvi49=0; 
if qvi50=99 then qvi50=0; 
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi 13+qvi3 l +qvi6+qvi l 9+qvi 1; 
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11 +qvi50+qvi37+qvi l 5+qvi32+qvi48+qvi52; 
fop=qvi26+qvi27+qvil 7+qvi4 l +qvi2l +qvi28+qvi14+qvi47; 
bea=qvi29+qvi23+qvi24+qvi35+qvi39+qvi l 8+qvi5+qvi3+qvi25 ; 
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l +qvi12; 
if sss 1 =O then sss=.; 
if dis 1 =O then dis=.; 
if fop 1 =O then fop=.; 
if beal =O then bea=.; 
ifceal =O then cea=.; 
label totcomp= 'adherence to AV drugs'; 
label qil = 'age'; 
label qi2='gender'; 
label qi3= 'health status'; 
label qi4='ethnicity'; 
label qi5='education'; 
label qi6='employment'; 
label qi7='living anangement'; 
label qi18a ='insurance'; 
label qi19='income'; 
label qi24='body pain' ; 
label qi29='how long ago diagnosed'; 
label qi31 ='t cell coW1t'; 
/* new variable 'gender' created*/ 
gender=.; 
if qi2= 'm' then gender=l; 
else if qi2= 'f then gender=2; 
/* variable age categorized into three categories*/ 
if qi 1 It 35 then qi 1 =3; 
else if qi 1 ge 35 and qi 1 le 41 then qi 1 =2; 
else if qil ge 42 then qil=l; 
/* variab le etlrnicity dichotomized to whites or non whites*/ 
if qi4=0 then qi4=.; 
else if qi4=1 then qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
I* variable education dichotomized */ 
if qi5=0 then qi5=.; 
else if qi5 It 12 then qi5=1; 
else if qi5 ge 12 then qi5=0; 
/* variable employment dichotomized */ 
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if qi6=0 then qi6=.; 
else if qi6=1 or qi6=2 then qi6=0; 
else if qi6=3 then qi6=1; 
/* variable li ving arrangement dichotomized */ 
if qi7=0 then qi7=.; 
else if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
!*variable health status dichotomized */ 
if qi3=0 then qi3=.; 
else if qi3=1 or qi3=2 or qi3=3 then qi3=0; 
else ifqi3=4 or qi3=5 then qi3=1; 
!* variab le insurance dichotomized*/ 
if qil 8a=O then qi! 8a=.; 
ifqil8a=2 then qil8a=l; 
else if qi l 8a=1 then qil 8a=O; 
/* variable income dichotomized*/ 
if qil9=0 then qil9=.; 
else ifqil9=1 thenqil9=1; 
else if qil9=2 or qil9=3 or qil9=4 or qil9=5 then qil9=0; 
I* variable body pain dichotomized*/ 
if qi24=0 then qi24=.; 
else if qi24=1 or qi24=2 or qi24=3 then qi24=0; 
else if qi24=4 or qi24=5 or qi24=6 then qi24=1; 
/*variable how long ago diagnosed categorized*/ 
if qi29=0 then qi29=.; 
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3; 
else if qi29=5 then qi29=2; 
else if qi29=6 then qi29=1; 
/* variable T cell count dichotomized*/ 
if qi31 =O then qi31 =.; 
else if qi31 =1 or qi31 =2 then qi31 =O; 
else if qi31 = 3 or qi31 =4 then qi31 =1; 
sssmed=.; 
if sss It 30 or sss ge 37 then sssmed= O; 
else if sss ge 30 and sss It 37 then sssmed=l ; 
if sss 1 =O then sssmed=.; 
ssshigh=.; 
if sss ge 37 then ssshigh=l ; 
else if sss It 37 then ssshigh=O; 
if sss 1 =O then ssshigh=.; 
fop high=.; 
if fop GE 29 then fophigh=l; 
else if fop LT 29 then fophigh=O; 
if fop 1 =O then fophigh=. ; 
fopmed=.; 
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if fop GE 23 and fop LT 29 then fopmed=l; 
else if fop GE 29 or fop LT 23 then fopmed=O; 
if fop 1 =O then fopmed=.; 
dishigh=.; 
if dis GE 39 then dishigh= l; 
else if dis LT 39 then dishigh=O; 
if dis 1 =O then dishigh=.; 
dismed=.; 
if dis GE 33 and dis LT 39 then dismed=l; 
else if dis GE 39 or dis LT 33 then dismed=O; 
if dis 1 =O then dismed=.; 
beahigh=.; 
ifbea GE 24 then beahigh=l; 
else ifbea LT 24 then beahigh=O; 
ifbeal =O then beahigh=.; 
beamed=.; 
ifbea GE 19 and bea LT 24 then beamed=l; 
else if bea GE 24 or bea LT 19 then beamed=O; 
if bea 1 =O then beamed=.; 
ceahigh=.; 
ifcea GE 31 then ceahigh=l ; 
else ifcea LT 31 then ceahigh=O; 
if ceal =O then ceahigh=.; 
ceamed=.; 
if cea GE 25 and cea LT 31 then ceamed=l; 
else ifcea GE 31 or cea LT 25 then ceamed=O; 
ifceal =O then ceamed=.; 
proc format; 
value adherence 1 = 'adl1erent' 
O= 'nonadherent'; 
proc univariate normal plot; 
var qil qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31; 
proc freq; 
tables totcomp qil qi2 qi3 qi4 qi5 qi6 qi7 qil 8a qi19 
qi24 qi29 qi31 ssshigh sssmed; 
format totcomp adherence.; 
proc logistic descending; 
model totcomp= ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1 ) lackfit risklimits; run; 
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/*SAS PROGRAM TO DICHOTOMIZE PATI ENTS ON ANTIRETROVIRAL DRUGS AS 
BEING ADH ERENT OR NON ADHERENT 
BASED ON MEDICATION ADH ERENCE SCALE.*/ 
options nocenter linesize=72; 
libname saurabh 'c:\Documents and Settings\Erabus\DESKTOP\saurabb'; 
data saurabh3 ; 
set saurabh.hivsurv; 
if qiilx4=0 then qiilx4=99; 
if qiilx5=0 then qiilx5=99; 
if qiilx6=0 then qiilx6=99; 
if qii 1 x7=0 then qii 1 x7=99; 
if qiilx8=0 then qiilx8=99; 
ifqiilx9=0 then qiilx9=99; 
if qii2x4=0 then qii2x4=99; 
if qii2x5=0 then qii2x5=99; 
if qii2x6=0 then qii2x6=99; 
if qii2x7=0 then qii2x7=99; 
if qii2x8=0 then qii2x8=99; 
if qii2x9=0 then qii2x9=99; 
if qii3x4=0 then qii3x4=99; 
if qii3x5=0 then qii3x5=99; 
if qii3x6=0 then qii3x6=99; 
if qii3x7=0 then qii3x7=99; 
if qii3x8=0 then qii3x8=99; 
if qii3x9=0 then qii3x9=99; 
maslx= qiilx4+qii lx5+qii lx6+qiilx7+qii 1x8+qii1 x9; 
ifmasl GE 109 then masl =O; 
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
ifmas2x GE 109 then mas2=0; 
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
ifmas3x GE 109 then mas3=0; 
data saurabh6; 
set saurabh3 ; 
if qiilx4=99 then qiilx4=0; 
if qiilx5=99 then qiilx5=0; 
if qiilx6=99 then qiilx6=0; 
if qii I x7=99 then qii 1 x7=0; 
ifqiilx8=99 then qiilx8=0; 
ifqiilx9=99 then qiilx9=0; 
mas I =qii I x4+qii I x5+qii I x6+qii I x7+qii lx8+qii 1 x9; 
if mas I x=O then mas 1 =O; 
if qii2x4=99 then qii2x4=0; 
if qii2x5=99 then qii2x5=0; 
if qii2x6=99 then qii2x6=0; 
if qii2x7=99 then qii2x7=0; 
if qii2x8=99 then qii2x8=0; 
if qii2x9=99 then qii2x9=0; 
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
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ifmas2x=O then mas2=0; 
if qii3x4=99 then qii3x4=0; 
if qii3x5=99 then qii3x5=0; 
if qii3x6=99 then qii3x6=0; 
if qii3x7=99 then qii3x7=0; 
if qii3x8=99 then qii3x8=0; 
if qii3x9=99 then qii3x9=0; 
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
if mas3x=O then mas3=0; 
ifqiilx= 'bactrim' then masl=O; 
if qiilx= 'acyclovir' then masl=O; 
if qii 1 x= 'pentamidine' then mas 1 =O; 
if qii 1 x= 'zoloft' then mas 1 =O; 
if qii 1 x= 'crixivan' then mas 1 =O; 
if qiilx= 'ritonavir' then masl=O; 
if qii 1 x= 'saquinavir' then mas 1 =O; 
if qii2x= 'bactrim' then mas2=0; 
if qii2x= 'dapsone' then mas2=0; 
if qii2x= 'leucovorin' then mas2=0; 
if qii2x= 'ms contin' then mas2=0; 
if qii2x= 'theodur' then mas2=0; 
if qii2x= 'crixivan' then mas2=0; 
if qii2x= 'saquinavir' then mas2=0; 
if qii2x= 'indinavir' then mas2=0; 
if qii2x= 'ritonavir' then mas2=0; 
if qii3x= 'acyclovir' then mas3=0; 
if qii3x= 'bactrin1' then mas3=0; 
if qii3x= 'biaxin' then mas3=0; 
if qii3x= 'clotTirnazole' then mas3=0; 
if qii3x= 'compazine' then mas3=0; 
if qii3x= 'dapsone' then mas3=0; 
if qii3x= 'diltiazem' then mas3=0; 
if qii3x= 'fluconazole' then mas3=0; 
if qii3x= 'mellaril' then mas3=0; 
if qii3x= 'minocycline' then mas3=0; 
if qii3x= 'motrin' then mas3=0; 
if qii3x= 'oxandrin' then mas3=0; 
if qii3x= 'vasotec' then mas3=0; 
if qii3x= 'zantac' then mas3=0; 
if qii3x= 'zovirax' then mas3=0; 
if qii3x= 'crixivan' then mas3=0; 
if qii3x= 'indinavir' then mas3=0; 
if qii3x= 'invirase' then mas3=0; 
if qii3x= 'norvir' then mas3=0; 
if qii3x= 'ritonavir' then mas3=0; 
if qii3x= 'saquinavir' then mas3=0; 
totmas=mas 1 +mas2+mas3 ; 
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3 ; 
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl =O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2; 
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( ifmasl NE 0 and rnas2=0 and mas3=0 then totrnas=totrnas; ifmasl=O and mas2 NE 0 and mas3=0 then totrnas=totrnas; 
ifrnasl=O and mas2=0 and mas3 NE 0 then totrnas=totrnas; 
iftotrnas LT 6 then delete; 
totrnas 1 =12-totrnas; 
if totrnas 1 =6 then totrnas 1 =I; 
else iftotrnasl LT 6 then totrnasl=O; 
if qvi 1 =O then qvi 1 =99; 
if qvi2=0 then qvi2=99; 
if qvi3=0 then qvi3=99; 
if qvi4=0 then qvi4=99; 
if qvi5=0 then qvi5=99; 
if qvi6=0 then qvi6=99; 
if qvi7=0 then qvi7=99; 
if qvi8=0 then qvi8=99; 
if qvi9=0 then qvi9=99; 
if qvilO=O then qvi10=99; 
if qvil 1=0 then qvil 1=99; 
if qvil2=0 then qvi12=99; 
if qvi 13=0 then qvi 13=99; 
if qvi 14=0 then qvi 14=99; 
ifqvil5=0 then qvil5=99; 
if qvil6=0 then qvil6=99; 
if qvil 7=0 then qvil 7=99; 
if qvi 18=0 then qvi 18=99; 
if qvi 19=0 then qvi 19=99; 
if qvi20=0 then qvi20=99; 
if qvi2 l =O then qvi2 l =99; 
if qvi22=0 then qvi22=99; 
if qvi23=0 then qvi23=99; 
if qvi24=0 then qvi24=99; 
if qvi25=0 then qvi25=99; 
if qvi26=0 then qvi26=99; 
if qvi27=0 then qvi27=99; 
if qvi28=0 then qvi28=99; 
if qvi29=0 then qvi29=99; 
if qvi30=0 then qvi30=99; 
if qvi3 l =O then qvi3 l =99; 
if qvi32=0 then qvi32=99; 
if qvi33=0 then qvi33=99; 
if qvi34=0 then qvi34=99; 
if qvi35=0 then qvi35=99; 
if qvi36=0 then qvi36=99; 
if qvi37=0 then qvi37=99; 
if qvi38=0 then qvi38=99; 
if qvi39=0 then qvi39=99; 
if qvi40=0 then qvi40=99; 
if qvi4 l =O then qvi4 l =99; 
if qvi42=0 then qvi42=99; 
if qvi43=0 then qvi43=99; 
if qvi44=0 then qvi44=99; 
if qvi45=0 then qvi45=99; 
if qvi46=0 then qvi46=99; 
if qvi4 7=0 then qvi4 7=99; 
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if qvi48=0 then qvi48=99; 
if qvi49=0 then qvi49=99; 
if qvi50=0 then qvi50=99; 
sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvil; 
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvil1+qvi50+qvi37+qvil5+qvi32+qvi48+qvi52; 
fop 1=qvi26+qvi27+qvi17+qvi41 +qvi21+qvi28+qvil4+qvi4 7; 
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25; 
cea 1 =qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12; 
ifsssl GT 149 then sssl=O; 
if dis 1 GT 154 then dis 1 =O; 
iffopl GT 134 then fopl=O; 
ifbeal GT 139 then beal=O; 
ifceal GT 139 then ceal=O; 
run; 
data saurabh7; 
set saurabh6; 
if qvi 1 =99 then qvi 1 =O; 
if qvi2=99 then qvi2=0; 
if qvi3=99 then qvi3=0; 
if qvi4=99 then qvi4=0; 
if qvi5=99 then qvi5=0; 
if qvi6=99 then qvi6=0; 
if qvi7=99 then qvi7=0; 
if qvi8=99 then qvi8=0; 
if qvi9=99 then qvi9=0; 
if qvi 10=99 then qvi 10=0; 
if qvi 11 =99 then qvi 11 =O; 
if qvi 12=99 then qvi 12=0; 
if qvi 13=99 then qvi 13=0; 
if qvi14=99 then qvi14=0; 
if qvi15=99 then qvi15=0; 
if qvi16=99 then qvil6=0; 
if qvi 17=99 then qvi 17=0; 
if qvi 18=99 then qvi 18=0; 
if qvi 19=99 then qvi 19=0; 
if qvi20=99 then qvi20=0; 
if qvi21 =99 then qvi21 =O; 
if qvi22=99 then qvi22=0; 
if qvi23=99 then qvi23=0; 
if qvi24=99 then qvi24=0; 
if qvi25=99 then qvi25=0; 
if qvi26=99 then qvi26=0; 
if qvi27=99 then qvi27=0; 
if qvi28=99 then qvi28=0; 
if qvi29=99 then qvi29=0; 
if qvi30=99 then qvi30=0; 
if qvi31 =99 then qvi31 =O; 
if qvi32=99 then qvi32=0; 
if qvi33=99 then qvi33=0; 
if qvi34=99 then qvi34=0; 
if qvi35=99 then qvi35=0; 
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( if qvi36=99 then qvi36=0; if qvi37=99 then qvi37=0; 
if qvi38=99 then qvi38=0; 
if qvi39=99 then qvi39=0; 
if qvi40=99 then qvi40=0; 
if qvi41 =99 then qvi41 =O; 
if qvi42=99 then qvi42=0; 
if qvi43=99 then qvi43=0; 
if qvi44=99 then qvi44=0; 
if qvi45=99 then qvi45=0; 
if qvi46=99 then qvi46=0; 
ifqvi47=99 then qvi47=0; 
if qvi48=99 then qvi48=0; 
if qvi49=99 then qvi49=0; 
if qvi50=99 then qvi50=0; 
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi l 3+qvi31+qvi6+qvi19+qvi 1; 
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11 +qvi50+qvi37+qvi 15+qvi32+qvi48+qvi52; 
fop=qvi26+qvi27+qvi l 7+qvi41 +qvi21+qvi28+qvil4+qvi4 7; 
bea=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25; 
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12; 
if sss 1 =O then sss=.; 
if dis 1 =O then dis=.; 
iffopl=O then fop=.; 
ifbeal=O then bea=.; 
if cea 1 =O then cea=.; 
label totmasl = 'adherence to AV dmgs'; 
label qi 1 = 'age'; 
label qi2='gender'; 
label qi3= 'health status'; 
label qi4='ethnicity'; 
label qi5='education'; 
label qi6='employment'; 
label qi7='l iving arrangement'; 
label qi 18a ='insurance'; 
label qi19='income'; 
label qi24='body pain'; 
label qi29='how long ago diagnosed'; 
label qi31='t cell cow1t'; 
/*new variable 'gender' created*/ 
gender=.; 
if qi2= 'm' then gender=!; 
else if qi2= 'f then gender=2; 
/* variable age categorized into three categories*/ 
ifqil lt35thenqi1 =3; 
else if qil ge 35 and qi 1 le 41 then qi 1 =2 ; 
else if qi 1 ge 42 then qil =I; 
/* variable ethnicity dichotomized to whites or non whites*/ 
if qi4=0 then qi4=.; 
else ifqi4=1 then qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
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/* va1iable education dichotomized*/ 
if qi5=0 then qi5=.; 
else if qi5 It 12 then qi5=1; 
else if qi5 ge 12 then qi5=0; 
/* variable employment dichotomized*/ 
if qi6=0 then qi6=.; 
else if qi6=1 or qi6=2 then qi6=0; 
else if qi6=3 then qi6=1; 
I* variab le liviug arrangement dichotomized */ 
if qi7=0 then qi7=.; 
else if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
I* variable health status dichotomized */ 
if qi3 =0 then qi3=.; 
else if qi3=1 or qi3=2 or qi3=3 then qi3=0; 
else if qi3=4 or qi3=5 then qi3=1; 
!* variable insurance dichotomized */ 
ifqi18a=O then qi18a=.; 
ifqi18a=2 then qi18a= l ; 
else ifqi18a=l thenqi18a=O; 
I* variable income dichotomized*/ 
if qi 19=0 then qi 19=. ; 
else if qi 19=1 then qi 19=1; 
else if qi19=2 or qil9=3 or qi19=4 or qil9=5 then qi19=0; 
/* variable body pain dichotomized*/ 
if qi24=0 then qi24=.; 
else if qi24=1 or qi24=2 or qi24=3 then qi24=0; 
else if qi24=4 or qi24=5 or qi24=6 then qi24=1; 
/* va1iable how long ago diagnosed categorized*/ 
if qi29=0 then qi29=.; 
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3; 
else if qi29=5 then qi29=2 ; 
else if qi29=6 then qi29=1; 
I* va1iab le T cell cow1t dichotomized*/ 
if qi31 =O then qi31 =.; 
else if qi31 = 1 or qi31 =2 then qi31 =O; 
else if qi31 = 3 or qi31 =4 then qi31 =1; 
sssmed=.; 
if sss It 30 or sss ge 37 then sssmed= O; 
else if sss ge 30 and sss It 37 then sssmed=l; 
if sss 1 =O then sssmed=.; 
ssshigh=.; 
if sss ge 37 then ssshigh=l ; 
else if sss It 37 then ssshigh=O; 
if sss 1 =O then ssshigh=.; 
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( fophigh=.; if fop GE 29 then fophigh=l ; 
else if fop LT 29 then fophigh=O; 
if fop 1 =O then fophigh=.; 
fopmed=.; 
if fop GE 22 and fop LT 29 then fopmed=l; 
else if fop GE 29 or fop LT 22 then fopmed=O; 
iffopl =O then fopmed=.; 
dishigh=.; 
if dis GE 39 then dishigh=l; 
else if dis LT 39 then dishigh=O; 
if dis 1 =O then dishigh=.; 
dismed=.; 
if dis GE 33 and dis LT 39 then dismed=l; 
else if dis GE 39 or dis LT 33 then dismed=O; 
if dis 1 =O then dismed=.; 
beahigh=.; 
if bea GE 24 then beahigh=l; 
else ifbea LT 24 then beahigh=O; 
ifbeal =O then beahigh=.; 
beamed=.; 
ifbea GE 19 and bea LT 24 then beamed=l; 
else ifbea GE 24 or bea LT 19 then beamed=O; 
if bea 1 =O then beamed=.; 
ceahigh=.; 
ifcea GE 31 then ceahigh=l; 
else ifcea LT 31 then ceahigh=O; 
if cea 1 =O then ceahigh=.; 
ceamed=.; 
ifcea GE 25 and cea LT 31 then ceamed=l; 
else ifcea GE 31 or cea LT 25 then ceamed=O; 
if cea 1 =O then ceamed=.; 
proc format ; 
value adherence 1 = 'adJ1erent' 
O= 'nonadherent'; 
proc univariate normal plot; 
var qil qi3 qi4 qi5 qi6 qi7 qil8a qi19 
qi24 qi29 qi3 l; 
proc freq ; 
tables totmasl qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 ssshigh sssmed; 
format totmasl adherence.; 
proc logistic descending; 
model totmasl = ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qil8a qi19 
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1) lackfit risklimits; run; 
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/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON PROTEASE INHIBITOR 
DRUGS AS BEING ADHERENT OR NON ADHERENT BASED ON PERCENT AGE 
ADHERENCE DEFINITIONS.*/ 
options nocenter linesize=72; 
libname saurabh 'c:\Documents and Settings\Erabus\DESKTOP\saurabh'; 
data saurabh3; 
set saurabh.hivsurv; 
ifqiilx= 'bactrim' then qiilx2a=O; 
if qiilx= 'acyclovir' then qiilx2a=O; 
if qiilx= 'pentam.idine' then qiilx2a=O; 
if qiilx= 'zoloft' then qii lx2a=O; 
if qiilx= '3tc' then qiilx2a=O; 
ifqiilx= 'azt' then qiilx2a=O; 
if qiilx= 'd4t' then qiilx2a=O; 
ifqiilx= 'ddc' then qiilx2a=O; 
ifqiilx= 'ddi' then qiilx2a=O; 
if qiilx= 'zerit' then qiilx2a=O; 
if qiilx= 'epivir' then qiilxla=O; 
if qiilx2a=O then qiilx13=.; 
ifqiilx13=99 then qiilx2a=.; 
if qiilx2a=l then qiilx2a=8; 
if qiilx2a=2 then qii lx2a=l2; 
if qiilx2a=3 then qiilx2a=l5; 
if qiilx2a=4 then qiilx2a=30; 
if qiilx2a=S then qiilx2a=60; 
if qiilx2a=6 then qiilx2a=90; 
if qiilx2a=7 then qiilx2a=160; 
ifqiilx2a=8 then qiilx2a=200; 
medl= qiilx13/qiilx2a; 
compl=l-medl; 
percompl=compl *100; 
if qii2x= 'bactrim' then qii2x2a=O; 
if qii2x= 'dapsone' then qii2x2a=O; 
if qii2x= 'leucovorin' then qii2x2a=O; 
if qii2x= 'ms contin' then qii2x2a=O; 
if qii2x= 'theodur' then qii2x2a=O; 
if qii2x= '3tc' then qii2x2a=O; 
if qii2x= 'azt' then qii2x2a=O; 
if qii2x= 'd4t' then qii2x2a=O; 
if qii2x= 'ddc' then qii2x2a=O; 
if qii2x= 'ddi' then qii2x2a=O; 
if qii2x= 'epivir' then qii2x2a=O; 
if qii2x= 'zerit' then qii2x2a=O; 
if qii2x2a=O then qii2x13=.; 
if qii2x13=99 then qii2x2a=.; 
if qii2x2a=1 then qii2x2a=8; 
if qii2x2a=2 then qii2x2a=l2; 
if qii2x2a=3 then qii2x2a=l5; 
if qii2x2a=4 then qii2x2a=30; 
if qii2x2a=S then qii2x2a=60; 
if qii2x2a=6 then qii2x2a=90; 
if qii2x2a=7 then qii2x2a=l60; 
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if qii2x2a=8 then qii2x2a=200; 
med2= qii2xl3/qii2x2a; 
comp2=1-med2; 
percomp2=comp2*100; 
if qii3x= 'acyclovir' then qii3x2a=O; 
if qii3x= 'bactrim' then qii3x2a=O; 
if qii3x= 'biaxi11' then qii3x2a=O; 
if qii3x= 'clotrimazole' then qii3x2a=O; 
if qii3x= 'compazine' then qii3x2a=O; 
if qii3x= 'dapsone' then qii3x2a=O; 
if qii3x= 'diltiazem' then qii3x2a=O; 
if qii3x= 'fluconazole' then qii3x2a=O; 
if qii3x= 'mellaril' then qii3x2a=O; 
if qii3x= 'minocycline' then qii3x2a=O; 
if qii3x= 'motrin' then qii3x2a=O; 
if qii3x= 'oxanclrin' then qii3x2a=O; 
if qii3x= 'vasotec' then qii3x2a=O; 
if qii3x= 'zantac' then qii3x2a=O; 
if qii3x= 'zovirax' then qii3x2a=O; 
if qiilx= 'azt' then qiilx2a=O; 
if qiilx= '3tc' then qiilx2a=O; 
ifqiilx= 'd4t' then qiilx2a=O; 
ifqiilx= 'epivir' then qiilx2a=O; 
ifqii3x2a=O then qii3xl3=.; 
if qii3x13=99 then qii3x2a=.; 
if qii3x2a=l then qii3x2a=8; 
if qii3x2a=2 then qii3x2a=l2; 
if qii3x2a=3 then qii3x2a=l5; 
if qii3x2a=4 then qii3x2a=30; 
if qii3x2a=5 then qii3x2a=60; 
if qii3x2a=6 then qii3x2a=90; 
if qii3x2a=7 then qii3x2a=l 60; 
if qii3x2a=8 then qii3x2a=200; 
med3= qii3x13/qii3x2a; 
comp3=1-med3; 
percomp3=comp3*100; 
if percomp 1 =. then percomp 1 =O; 
if percomp2=. then percomp2=0; 
ifpercomp3=. then percomp3=0; 
totcomp= percomp 1 +percomp2+percomp3; 
ifpercompl=O and percomp2 NE 0 and percomp3 NE 0 then totcomp= totcomp/2; 
ifpercompl NE 0 and percomp2= 0 and percomp3 NE 0 then totcomp= totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3= 0 then totcomp=totcomp/2; 
ifpercompl NE 0 and percomp2 NE 0 and percomp3 NE 0 then totcomp=totcomp/3; 
if percomp 1 NE 0 and percomp2=0 and percomp3= 0 then totcomp= totcomp; 
ifpercompl=O and percomp2 NE 0 and percomp3= 0 then totcomp= totcomp; 
ifpercompl=O and percomp2=0 and percomp3 NE 0 then totcomp= totcomp; 
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if totcomp=O then delete; 
if totcomp =100 then totcomp=l; 
else if totcomp LT 100 then totcomp=O; 
if qvil =O then qvil =99; 
if qvi2=0 then qvi2=99; 
if qvi3=0 then qvi3=99; 
if qvi4=0 then qvi4=99; 
if qvi5=0 then qvi5=99; 
if qvi6=0 then qvi6=99; 
if qvi7=0 then qvi7=99; 
if qvi8=0 then qvi8=99; 
if qvi9=0 then qvi9=99; 
if qvilO=O then qvil0=99; 
if qvi 11 =O then qvi 11 =99; 
if qvil2=0 then qvil2=99; 
if qvi 13=0 then qvi 13=99; 
if qvi 14=0 then qvi 14=99; 
if qvil5=0 then qvil5=99; 
if qvi 16=0 then qvi 16=99; 
if qvi 17=0 then qvi 17=99; 
if qvi 18=0 then qvi 18=99; 
if qvi 19=0 then qvi 19=99; 
if qvi20=0 then qvi20=99; 
if qvi2 l =O then qvi2 l =99; 
if qvi22=0 then qvi22=99; 
if qvi23=0 then qvi23=99; 
if qvi24=0 then qvi24=99; 
if qvi25=0 then qvi25=99; 
if qvi26=0 then qvi26=99; 
if qvi27=0 then qvi27=99; 
if qvi28=0 then qvi28=99; 
if qvi29=0 then qvi29=99; 
if qvi30=0 then qvi30=99; 
if qvi3 l =O then qvi3 l =99; 
if qvi32=0 then qvi32=99; 
if qvi33=0 then qvi33=99; 
if qvi34=0 then qvi34=99; 
if qvi35=0 then qvi35=99; 
if qvi36=0 then qvi36=99; 
if qvi37=0 then qvi37=99; 
if qvi38=0 then qvi38=99; 
if qvi39=0 then qvi39=99; 
if qvi40=0 then qvi40=99; 
if qvi4 l =O then qvi4 l =99; 
if qvi42=0 then qvi42=99; 
if qvi43=0 then qvi43=99; 
if qvi44=0 then qvi44=99; 
if qvi45=0 then qvi45=99; 
if qvi46=0 then qvi46=99; 
if qvi47=0 then qvi47=99; 
if qvi48=0 then qvi48=99; 
if qvi49=0 then qvi49=99; 
if qvi50=0 then qvi50=99; 
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sss 1=qvi4+qvi34+qvi22+qvi20+qvi16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1; 
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvi11+qvi50+qvi37+qvil5+qvi32+qvi48+qvi52; 
fopl =qvi26+qvi27+qvil 7+qvi41 +qvi21 +qvi28+qvi14+qvi47; 
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvi18+qvi5+qvi3+qvi25; 
cea 1 =qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12; 
ifsssl GT 149 then sssl=O; 
ifdisl GT 154 then disl=O; 
iffopl GT 134 then fopl=O; 
ifbeal GT 139 then beal=O; 
ifceal GT 139 then ceal=O; 
run; 
data saurabh7; 
set saurabh3; 
if qvi 1 =99 then qvi 1 =O; 
if qvi2=99 then qvi2=0; 
if qvi3=99 then qvi3=0; 
if qvi4=99 then qvi4=0; 
if qvi5=99 then qvi5=0; 
if qvi6=99 then qvi6=0; 
if qvi7=99 then qvi7=0; 
if qvi8=99 then qvi8=0; 
if qvi9=99 then qvi9=0; 
if qvi 10=99 then qvi 1 O=O; 
if qvi 11 =99 then qvi 11 =O; 
if qvi 12=99 then qvi 12=0; 
if qvi 13=99 then qvi 13=0; 
if qvi 14=99 then qvi 14=0; 
if qvi 15=99 then qvi 15=0; 
if qvi 16=99 then qvil 6=0; 
ifqvi17=99 then qvi17=0; 
if qvi 18=99 then qvi 18=0; 
if qvi 19=99 then qvi 19=0; 
if qvi20=99 then qvi20=0; 
if qvi21 =99 then qvi21 =O; 
if qvi22=99 then qvi22=0; 
if qvi23=99 then qvi23=0; 
if qvi24=99 then qvi24=0; 
if qvi25=99 then qvi25=0; 
if qvi26=99 then qvi26=0; 
if qvi27=99 then qvi27=0; 
if qvi28=99 then qvi28=0; 
if qvi29=99 then qvi29=0; 
if qvi30=99 then qvi30=0; 
if qvi31 =99 then qvi31 =O; 
if qvi32=99 then qvi32=0; 
if qvi33=99 then qvi33=0; 
if qvi34=99 then qvi34=0; 
if qvi35=99 then qvi35=0; 
if qvi36=99 then qvi36=0; 
if qvi37=99 then qvi37=0; 
if qvi38=99 then qvi38=0; 
if qvi39=99 then qvi39=0; 
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if qvi40=99 then qvi40=0; 
if qvi4 I =99 then qvi4 I =O; 
if qvi42=99 then qvi42=0; 
if qvi43=99 then qvi43=0; 
if qvi44=99 then qvi44=0; 
if qvi45=99 then qvi45=0; 
if qvi46=99 then qvi46=0; 
if qvi47=99 then qvi47=0; 
if qvi48=99 then qvi48=0; 
if qvi49=99 then qvi49=0; 
if qvi50=99 then qvi50=0; 
sss=qvi4+qvi34+qvi22+qvi20+qvi I 6+qvi49+qvi I 3+qvi3 I +qvi6+qvi I 9+qvi I; 
dis=qvi40+qvi30+qvi33+qvi9+qvi I O+qvi I I +qvi50+qvi37+qviI 5+qvi32+qvi48+qvi52; 
fop=qvi26+qvi2 7 +qvi I 7+qvi4 I +qvi2 I +qvi28+qvi I 4+qvi4 7; 
bea=qvi29+qvi23+qvi24+qvi3 5+qvi3 9+qvi I 8 +qvi5+qvi3+q vi2 5; 
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5 I +qviI2; 
if sss I =O then sss=.; 
if dis I =O then dis=.; 
iffopI=O then fop=.; 
ifbeaI=O then bea=.; 
if cea I =O tl1en cea=.; 
label totmasI ='adherence to AV drugs'; 
label qi I= 'age'; 
label qi2='gender'; 
label qi3= 'health status'; 
label qi4='ethnicity'; 
label qi5='education'; 
label qi6='employment'; 
label qi7='1iving aITangement'; 
label qiI 8a ='insurance'; 
label qiI9='income'; 
label qi24='body pain'; 
label qi29='how long ago diagnosed'; 
label qi3 I ='t cell count'; 
I* new variable 'gender' created*/ 
gender=.; 
if qi2= 'm' then gender= I; 
else if qi2= 'f then gender=2; 
I* variable age categorized into three categories*/ 
if qi I It 35 then qi I =3; 
else ifqiI ge 35 and qiI le 41 then qiI=2; 
else if qi I ge 42 then qiI=l; 
I* variable ethnicity dichotomized to whites or non whites*/ 
if qi4=0 then qi4=.; 
else if qi4=1 ilien qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 ilien qi4=0; 
I* variable education dichotomized */ 
if qi5=0 then qi5=.; 
else if qi5 It 12 ilien qi5=1; 
else if qi5 ge 12 then qi5=0; 
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/* variable employment dichotomized*/ 
if qi6=0 then qi6=.; 
else if qi6=1 or qi6=2 then qi6=0; 
else if qi6=3 then qi6=1; 
/* variable living arrangement dichotomized */ 
if qi7=0 then qi7=.; 
else if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
I* variable health status dichotomized */ 
if qi3=0 then qi3=.; 
else if qi3=1 or qi3=2 or qi3=3 then qi3=0; 
else if qi3=4 or qi3=5 then qi3=1; 
/* variable insw-ance dichotomized */ 
ifqi18a=O then qi18a=.; 
if qi 18a=2 then qi 18a= 1; 
else ifqi18a=1 then qi18a=O; 
I* variable income dichotomized */ 
ifqi19=0 then qil9=.; 
else ifqi19=1 then qi19=1; 
else ifqi19=2 or qi19=3 or qil9=4 or qi19=5 then qi19=0; 
I* variable body pai11 dichotomized */ 
if qi.24=0 then qi24=.; 
else if qi24=1 or qi24=2 or qi.24=3 then qi24=0; 
else if qi24=4 or qi24=5 or qi.24=6 then qi24=1; 
/* variable how long ago diagnosed categorized*/ 
if qi29=0 then qi29=.; 
else if qi29= 1 or qi.29=2 or qi.29=3 or qi.29=4 then qi29=3; 
else if qi29=5 then qi.29=2; 
else if qi29=6 then qi29=1; 
/* variable T cell count dichotomized*/ 
ifqi31=0 then qi31 =.; 
else if qi31 = 1 or qi31 =2 then qi31 =O; 
else if qi31 =3 or qi.31 =4 then qi31 =l; 
sssmed=.; 
if sss lt 29 or sss ge 35 then sssmed= O; 
else if sss ge 29 and sss lt 35 then sssmed=l; 
if sss 1 =O then sssmed=.; 
ssshigh=.; 
if sss ge 35 then ssshigh=l; 
else if sss lt 35 then ssshigh=O; 
if sss 1 =O then ssshigh=.; 
fophigh=.; 
if fop GE 29 then fophigh=l; 
else if fop LT 29 then fophigh=O; 
iffopl =O then fophigh=.; 
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fopmed=.; 
if fop GE 23 and fop LT 29 then fopmed=l; 
else if fop GE 29 or fop LT 23 then fopmed=O; 
if fop 1 =O then fopmed=.; 
dishigh=.; 
if dis GE 39 then dishigh=l; 
else if dis LT 39 then dishigh=O; 
if dis 1 =O then dishigh=.; 
dismed=.; 
if dis GE 33 and dis LT 39 then dismed=l; 
else if dis GE 39 or dis LT 33 then dismed=O; 
if dis 1 =O then dismed=.; 
beahigh=.; 
ifbea GE 24 then beahigh=l; 
else ifbea LT 24 then beahigh=O; 
ifbeal=O then beahigh=.; 
beamed=.; 
ifbea GE 19 and bea LT 24 then beamed=l; 
else ifbea GE 24 or bea LT 19 then beamed=O; 
ifbeal=O then beamed=.; 
ceahigh=.; 
if cea GE 30 then ceahigh= 1; 
else if cea LT 30 then ceahigh=O; 
ifceal=O then ceahigh=.; 
ceamed=.; 
if cea GE 24 and cea LT 30 then ceamed=l; 
else if cea GE 31 or cea LT 24 then ceamed=O; 
if cea 1 =O then ceamed=.; 
proc format ; 
value adherence l = 'adherent' 
O= 'nonadherent'; 
proc univariate normal plot; 
var qil qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 ; 
proc freq; 
tables totcomp qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 ssshigh sssmed; 
format totcomp adherence. ; 
proc logistic descending; 
model totcomp= ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 / ctable pprob= (0 to 1 by .1) lackfit risklimits; run; 
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/*SAS PROGRAM TO DICHOTOMIZE PATIENTS ON PROTEASE INHIBITOR 
DRUGS AS BEING ADHERENT OR NON ADHERENT 
BASED ON MEDICATION ADHERENCE SCALE.*/ 
options nocenter linesize=72; 
libname saurabh 'c:\Docwnents and Settings\Erabus\DESKTOP\saurabh'; 
data saurabh3; 
set saurabh.hivsurv; 
if qiilx4=0 then qiilx4=99; 
if qiilx5=0 then qiilx5=99; 
ifqiilx6=0 then qiilx6=99; 
ifqiilx7=0 then qiilx7=99; 
if qiilx8=0 then qiilx8=99; 
if qii 1 x9=0 then qii 1 x9=99; 
if qii2x4=0 then qii2x4=99; 
if qii2x5=0 then qii2x5=99; 
if qii2x6=0 then qii2x6=99; 
if qii2x7=0 then qii2x7=99; 
if qii2x8=0 then qii2x8=99; 
if qii2x9=0 then qii2x9=99; 
if qii3x4=0 then qii3x4=99; 
if qii3x5=0 then qii3x5=99; 
if qii3x6=0 then qii3x6=99; 
if qii3x7=0 then qii3x7=99; 
if qii3x8=0 then qii3x8=99; 
if qii3x9=0 then qii3x9=99; 
maslx= qii lx4+qiilx5+qiilx6+qii lx7+qii lx8+qii lx9; 
ifmaslx GE 109 then masl=O; 
mas2x= qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
ifmas2x GE 109 then mas2=0; 
mas3x= qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
ifmas3x GE 109 then mas3=0; 
data saurabh5; 
set saurabh3; 
if qiilx4=99 then qiilx4=0; 
if qiilx5=99 then qiilx5=0; 
ifqiilx6=99 then qiilx6=0; 
ifqiilx7=99 then qiilx7=0; 
if qiilx8=99 then qiilx8=0; 
ifqiilx9=99 then qiilx9=0; 
mas 1=qii1x4+qii1x5+qii1x6+qii1x7+qii1x8+qii1 x9; 
ifmaslx=O then masl=O; 
if qii2x4=99 then qii2x4=0; 
if qii2x5=99 then qii2x5=0; 
if qii2x6=99 then qii2x6=0; 
if qii2x7=99 then qii2x7=0; 
if qii2x8=99 then qii2x8=0; 
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( 
if qii2x9=99 then qii2x9=0; 
mas2=qii2x4+qii2x5+qii2x6+qii2x7+qii2x8+qii2x9; 
if mas2x=O then mas2=0; 
if qii3x4=99 then qii3x4=0; 
if qii3x5=99 then qii3x5=0; 
if qii3x6=99 then qii3x6=0; 
if qii3x7=99 then qii3x7=0; 
if qii3x8=99 then qii3x8=0; 
if qii3x9=99 then qii3x9=0; 
mas3=qii3x4+qii3x5+qii3x6+qii3x7+qii3x8+qii3x9; 
ifmas3x=O then mas3=0; 
if qiilx= 'bact1im' then masl =O; 
if qii Ix= 'acyclovir' then mas I =O; 
if qiilx= 'pentam.idine' then masl=O; 
if qiilx= 'zoloft' then masl=O; 
ifqiilx= '3tc' then masl=O; 
if qiilx= 'azt' then masl=O; 
ifqiilx= 'd4t' then masl=O; 
ifqiilx= 'ddi' then masl =O; 
if qiilx= 'ddc' then masl=O; 
ifqiilx= 'epivir' then masl =O; 
if qiilx= 'zerit' then masl =O; 
if qii2x= 'bactrim' then mas2=0; 
if qii2x= 'dapsone' then mas2=0; 
if qii2x= 'leucovorin' then mas2=0; 
if qii2x= 'ms contin' then mas2=0; 
if qii2x= 'theodur' then mas2=0; 
if qii2x= 'Jtc' then mas2=0; 
if qii2x= 'azt' then mas2=0; 
if qii2x= 'd4t' then mas2=0; 
if qii2x= 'ddc' then mas2=0; 
if qiilx= 'ddi' then masl =O; 
if qiilx= 'epivir' then masl=O; 
if qiilx= 'zerit' then masl =O; 
if qii3x= 'acyclovir' then mas3=0; 
if qii3x= 'bactrim' then mas3=0; 
if qii3x= 'biaxin' then mas3=0; 
if qii3x= 'clotrimazole' then mas3=0; 
if qii3x= 'compazine' then mas3=0; 
if qii3x= 'dapsone' then mas3=0; 
if qii3x= 'diltiazem' then mas3=0; 
if qii3x= 'fluconazole' then mas3=0; 
if qii3x= 'mellaril' then mas3=0; 
if qii3x= 'minocycline' then mas3=0; 
if qii3x= 'motrin' then mas3=0; 
if qii3x= 'oxandrin' then mas3=0; 
if qii3x= 'vasotec' then mas3=0; 
if qii3x= 'zantac' then mas3=0; 
if qii3x= 'zovirax' then mas3=0; 
if qii3x= '3tc' then mas3=0; 
if qii3x= 'azt' then mas3=0; 
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if qii3x= 'd4t' then mas3=0; 
if qii3x= 'epivir' then mas3=0; 
totmas=mas 1 +mas2+mas3; 
ifmasl NE 0 and mas2 NE 0 and mas3 NE 0 then totmas= totmas/3; 
ifmasl NE 0 and mas2= 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl=O and mas2 NE 0 and mas3 NE 0 then totmas= totmas/2; 
ifmasl NE 0 and mas2 NE 0 and mas3=0 then totmas= totmas/2; 
if mas 1 NE 0 and mas2=0 and mas3=0 then totmas=totmas; 
if mas 1 =O and mas2 NE 0 and mas3=0 then totrnas=totmas; 
ifmasl=O and mas2=0 and mas3 NE 0 then totmas=totmas; 
if totmas LT 6 then delete; 
totmas 1 =12-totmas; 
iftotmasl = 6 then totmasl =1; 
else iftotrnasl LE 6 then totmasl =O; 
ifqvil=O then qvi1=99; 
if qvi2=0 then qvi2=99; 
if qvi3=0 then qvi3=99; 
if qvi4=0 then qvi4=99; 
if qvi5=0 then qvi5=99; 
if qvi6=0 then qvi6=99; 
if qvi7=0 then qvi7=99; 
if qvi8=0 then qvi8=99; 
if qvi9=0 then qvi9=99; 
if qvi 1 O=O then qvi 10=99; 
if qvi 11 =O then qvi 11 =99; 
ifqvi12=0 then qvi12=99; 
if qvi 13=0 then qvi 13=99; 
if qvi14=0 then qvi14=99; 
if qvi 15=0 then qvi 15=99; 
if qvi 16=0 then qvi 16=99; 
if qvil 7=0 then qvi 17=99; 
if qvi 18=0 then qvi 18=99; 
if qvi 19=0 then qvi 19=99; 
if qvi20=0 then qvi20=99; 
if qvi21 =O then qvi21 =99; 
if qvi22=0 then qvi22=99; 
if qvi23=0 then qvi23=99; 
if qvi24=0 then qvi24=99; 
if qvi25=0 then qvi25=99; 
if qvi26=0 then qvi26=99; 
if qvi27=0 then qvi27=99; 
if qvi28=0 then qvi28=99; 
if qvi29=0 then qvi29=99; 
if qvi30=0 then qvi30=99; 
if qvi31 =O then qvi31 =99; 
if qvi32=0 then qvi32=99; 
if qvi33=0 then qvi33=99; 
if qvi34=0 then qvi34=99; 
if qvi35=0 then qvi35=99; 
if qvi36=0 then qvi36=99; 
if qvi37=0 then qvi37=99; 
if qvi38=0 then qvi38=99; 
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if qvi39=0 then qvi39=99; 
if qvi40=0 then qvi40=99; 
if qvi4 l =O then qvi4 l =99; 
if qvi42=0 then qvi42=99; 
if qvi43=0 then qvi43=99; 
if qvi44=0 then qvi44=99; 
if qvi45=0 then qvi45=99; 
if qvi46=0 then qvi46=99; 
if qvi47=0 then qvi47=99; 
if qvi48=0 then qvi48=99; 
if qvi49=0 then qvi49=99; 
if qvi50=0 then qvi50=99; 
sss 1=qvi4+qvi34+qvi22+qvi20+qvil6+qvi49+qvi l 3+qvi3 l +qvi6+qvi l 9+qvi 1; 
dis 1=qvi40+qvi30+qvi33+qvi9+qvi1O+qvi11+qvi50+qvi37+qvi l 5+qvi32+qvi48+qvi52; 
fop 1=qvi26+qvi27+qvil7+qvi4 l +qvi2 l +qvi28+qvi l 4+qvi4 7; 
bea 1=qvi29+qvi23+qvi24+qvi35+qvi39+qvil8+qvi5+qvi3+qvi25; 
cea 1 =qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi5l+qvi12; 
ifsssl GT 149 then sssl=O; 
ifdisl GT 154 then disl=O; 
iffopl GT 134 then fopl=O; 
ifbeal GT 139 then beal=O; 
ifceal GT 139 then ceal=O; 
run; 
data saurabh7; 
set saurabh5; 
if qvil =99 then qvi 1 =O; 
if qvi2=99 then qvi2=0; 
if qvi3=99 then qvi3=0; 
if qvi4=99 then qvi4=0; 
if qvi5=99 then qvi5=0; 
if qvi6=99 then qvi6=0; 
if qvi7=99 then qvi7=0; 
if qvi8=99 then qvi8=0; 
if qvi9=99 then qvi9=0; 
if qvi 10=99 then qvi 1 O=O; 
if qvil 1 =99 then qvil 1 =O; 
if qvi12=99 then qvil2=0; 
if qvi 13=99 then qvi 13=0; 
if qvil4=99 then qvil4=0; 
if qvi15=99 then qvil5=0; 
if qvi 16=99 then qvi 16=0; 
if qvil 7=99 then qvil 7=0; 
if qvi 18=99 then qvi 18=0; 
if qvi 19=99 then qvi 19=0; 
if qvi20=99 then qvi20=0; 
if qvi21 =99 then qvi2 l =O; 
if qvi22=99 then qvi22=0; 
if qvi23=99 then qvi23=0; 
if qvi24=99 then qvi24=0; 
if qvi25=99 then qvi25=0; 
if qvi26=99 then qvi26=0; 
if qvi27=99 then qvi27=0; 
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if qvi28=99 then qvi28=0; 
if qvi29=99 then qvi29=0; 
if qvi30=99 then qvi30=0; 
if qvi31 =99 then qvi31 =O; 
if qvi32=99 then qvi32=0; 
if qvi33=99 then qvi33=0; 
if qvi34=99 then qvi34=0; 
if qvi35=99 then qvi35=0; 
if qvi36=99 then qvi36=0; 
if qvi37=99 then qvi37=0; 
if qvi38=99 then qvi38=0; 
if qvi39=99 then qvi39=0; 
if qvi40=99 then qvi40=0; 
if qvi41 =99 then qvi41 =O; 
if qvi42=99 then qvi42=0; 
if qvi43=99 then qvi43=0; 
if qvi44=99 then qvi44=0; 
if qvi45=99 then qvi45=0; 
if qvi46=99 then qvi46=0; 
if qvi47=99 then qvi47=0; 
if qvi48=99 then qvi48=0; 
if qvi49=99 then qvi49=0; 
if qvi50=99 then qvi50=0; 
sss=qvi4+qvi34+qvi22+qvi20+qvi 16+qvi49+qvi 13+qvi31+qvi6+qvi19+qvi 1; 
dis=qvi40+qvi30+qvi33+qvi9+qvi 1O+qvi11+qvi50+qvi37+qvi15+qvi32+qvi48+qvi52; 
fop=qvi26+qvi27+qvi 17+qvi41 +qvi21+qvi28+qvi14+qvi4 7; 
bea=qvi2 9+qvi23+qvi24+qvi3 5+qvi39+qvi18+qvi5+q vi3+qvi25; 
cea=qvi7+qvi44+qvi45+qvi42+qvi43+qvi46+qvi8+qvi51+qvi12; 
if sss 1 =O then sss=.; 
if dis 1 =O then dis=.; 
if fop 1 =O then fop=.; 
ifbeal=O then bea=.; 
ifceal=O then cea=.; 
label totmasl= 'adherence to AV drugs'; 
label qil= 'age'; 
label qi2='gender'; 
label qi3= 'health status'; 
label qi4='ethnicity'; 
label qi5='education'; 
label qi6='employment'; 
label qi7='living arrangement'; 
label qil8a ='insurance'; 
label qi19='income'; 
label qi24='body pain'; 
label qi29='how long ago diagnosed'; 
label qi3 l ='t cell count'; 
/* new variable 'gender' created*/ 
gender=.; 
if qi2= 'm' then gender=l; 
else if qi2= 'f then gender=O; 
/* variable age categorized into three catego1ies*/ 
if qil It 35 then qi 1 =3; 
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( elseifqil ge35andqil le41 thenqil =2 ; else ifqil ge 42 then qil=l; 
/* variab le etl111icity dichotomized to whites or nou whites*/ 
if qi4=0 then qi4=.; 
else if qi4= 1 then qi4=1; 
else if qi4=2 or qi4=3 or qi4=4 or qi4=5 or qi4=6 then qi4=0; 
/* variable education dichotomized*/ 
if qi5=0 then qi5=.; 
else if qi5 It 12 then qi5= 1; 
else if qi5 ge 12 then qi5=0; 
/* variable employment dichotomized */ 
if qi6=0 then qi6=.; 
else if qi6=1 or qi6=2 then qi6=0; 
else if qi6=3 then qi6=1; 
I* variable living ai.Tangement dichotomized */ 
if qi7=0 then qi7=.; 
else if qi7=1 then qi7=1; 
else if qi7=2 then qi7=0; 
/* variable health status dichotomized */ 
if qi3=0 then qi3=.; 
else if qi3=1 or qi3=2 or qi3=3 then qi3=0; 
else if qi3=4 or qi3=5 then qi3=1; 
/* variable insurance dichotomized */ 
if qi l 8a=O then qi l 8a=.; 
if qi18a=2 then qi18a=l; 
else if qil 8a=l then qi l 8a=O; 
/* variable income dichotomized*/ 
if qil 9=0 then qil 9=.; 
else if qil9=1 then qi 19=1; 
else if qil9=2 or qil9=3 or qil9=4 or qil9=5 then qil9=0; 
/* variable body pain dichotomized */ 
if qi24=0 then qi24=.; 
else if qi24=1 or qi24=2 or qi24=3 then qi24=0; 
else if qi24=4 or qi24=5 or qi24=6 then qi24=1; 
/* variable how long ago diagnosed categorized*/ 
if qi29=0 then qi29=. ; 
else if qi29= 1 or qi29=2 or qi29=3 or qi29=4 then qi29=3; 
else if qi29=5 then qi29=2; 
else if qi29=6 then qi29=1; 
I* variable T celJ count dichotomized*/ 
if qi3 l =O then qi3 l =.; 
else ifqi31= 1 or qi31 =2 then qi31=0; 
else if qi3 l = 3 or qi31 =4 then qi3 l =l; 
sssmed=.; 
if sss It 30 or sss ge 35 then sssmed= O; 
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( else if sss ge 30 and sss lt 35 then sssmed=l; if sss 1 =O then sssmed=.; 
ssshigh=.; 
if sss ge 35 then ssshigh=l; 
else if sss It 35 then ssshigh=O; 
if sss 1 =O then ssshigh=.; 
fophigh=.; 
if fop GE 29 then fophigh=l; 
else if fop LT 29 then fophigh=O; 
if fop 1 =O then fophigh=.; 
fopmed=.; 
if fop GE 23 and fop LT 29 then fopmed=l ; 
else if fop GE 29 or fop LT 23 then fopmed=O; 
if fop 1 =O then fopmed=.; 
dishigh=.; 
if dis GE 39 then dishigh=l ; 
else if dis LT 39 then dishigh=O; 
if disl =O then dishigh=.; 
dismed=.; 
if dis GE 34 and dis LT 39 then dismed=l; 
else if dis GE 39 or dis LT 34 then dismed=O; 
if dis 1 =O then dismed=.; 
beahigh=.; 
ifbea GE 25 then beahigh=l; 
else ifbea LT 25 then beahigh=O; 
ifbeal =O then beahigh=.; 
beamed=.; 
ifbea GE 20 and bea LT 25 then beamed=l; 
else if bea GE 25 or bea LT 20 then beamed=O; 
ifbeal =O then beamed=.; 
ceahigh=.; 
if cea GE 30 then ceahigh=l; 
else ifcea LT 30 then ceahigh=O; 
ifceal =O then ceahigh=.; 
ceamed=.; 
if cea GE 24 and cea LT 30 then ceamed=l; 
else if cea GE 30 or cea LT 24 then ceamed=O; 
if cea 1 =O then ceamed=.; 
proc format; 
value adherence 1 = 'adherent' 
O= 'nonadherent'; 
proc univariate normal plot; 
var qil qi3 qi4 qi5 qi6 qi7 qil 8a qil9 
qi24 qi29 qi3 l ; 
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proc freq; 
tables totmasl qil qi2 qi3 qi4 qi5 qi6 qi7 qi18a qi19 
qi24 qi29 qi31 ssshigh sssmed; 
format totmas 1 adherence.; 
proc logistic descending; 
model totmasl = ssshigh sssmed qil gender qi3 qi4 qi5 qi6 qi7 qil8a qil9 
qi24 qi29 qi3 l / ctable pprob= (0 to l by .1) lackfit risklinuts; 
run; 
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Appendix-III- Ways of coping with HIV 
Response options for the scale: 
1- Never 
2- Rarely 
3- Occasionally 
4- Often 
5- Very often 
Here are some ways that different people may cope with HIV and its treatment. 
There are no right or wrong answer. 
In the last month, HOW OFTEN did you think, feel, or do each item? (Please 
circle one number for each item. 
In the last month, I 
1. concentrate on the next step 
2. felt the only thing to do was wait 
3. did something just to do something 
4. talked to someone to find out more 
5. criticized or lectured myself 
6. tried not to close off options 
7. hoped a miracle would happen 
8. went along with faith 
9. went on as if nothing had happened 
10. tried to keep my feelings to myself 
11 . looked for the silver lining; looked on the bright side 
12. slept more than usual 
13. looked for sympathy and understanding 
14. was inspired to be creative 
15. tried to forget the whole thing 
16. tried to get professional help 
1 7. changed or grew as a person in a good way 
18. waited to see what would happen before acting 
19. made a plan of action and followed it 
20. let my feelings out somehow 
21 . came out of the experience better than before 
22. talked to someone who could do something 
23. tried to make myself feel better by eating, drinking, smoking, or drug use 
24. took a big chance and did something risky 
25. tried not to act too hastly 
26. found new faith 
27. rediscovered what is important in life 
28. changed something so thing will turn out 
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( 
29. avoided being with people 
30. didn' t let it get to me; refused to think about it 
31. asked a friend or relative for advise 
32. kept others from knowing how bad things were 
33. made light of it; refused to get too serious 
34. talked to someone about how I was feeling 
35. took it out on other people 
36. drew on past experiences from similar situations 
3 7. knew what had to be done, so increased efforts 
38. refused to believe it was happening 
39. came up with different solutions 
40. tried to keep my feelings from interfering 
41. changed something about myself 
42. wished the situation would go away or be over 
43. had fantasies/ wishes about how it might turn out 
44. prayed 
45. prepared for the worst 
46. went over in my mind what I would say or do 
47. though of how a person I admire would act 
48. reminded myself how much worst things could be 
49. tried to find out as much as I could 
50. treated the illness as a challenge 
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